跳到正文
原文
Nature 健康护理主题·· 2026-10-13AI 评分28

痤疮:流行病学、危险因素、发病机制、管理及前沿研究

Acne: epidemiology, risk factors, pathogenesis, management and cutting-edge research

AI 导读

这是一篇关于痤疮的综合综述,系统阐述了其流行病学、危险因素、发病机制、管理及最新研究进展。数据显示,痤疮是第八大常见疾病,影响全球超过9.4%的人口。文章指出,痤疮被视为一种与代谢、内分泌及心理状况相关的系统性炎症综合征,并探讨了包括痤疮疫苗、靶向生物制剂在内的新兴治疗技术方向。

正文

Introduction

Acne is a prevalent inflammatory dermatological condition that predominantly affects the pilosebaceous unit, particularly in the facial region, and is intricately associated with various systemic factors, including metabolic and endocrine disorders.1,2 It ranks as the eighth most prevalent disease globally, impacting over 9.4% of the worldwide population and causing a serious global disease burden.3,4,5,6 Acne encompasses various subtypes, including acne vulgaris, cystic acne, acne conglobata, and acne fulminans, with acne vulgaris representing 99% of pathological cases.7 The clinical phenotypes of acne exhibit similar pathogenic mechanisms and may coexist or transform within the same individual, yet each subtype is characterized by distinct molecular interactions and immune pathways. Acne is not merely a localized dermatological condition but is increasingly recognized as a clinical syndrome intricately linked to systemic health. Although the term “acne syndrome” has not yet gained widespread acceptance, an expanding body of research indicates its association with conditions such as hidradenitis suppurativa (HS), insulin resistance, polycystic ovary syndrome, metabolic disorders, and psychological comorbidities, including anxiety, depression, and reduced quality of life.8,9 Therefore, the view that acne is a systemic inflammatory disease or syndrome has received increasing attention from researchers, but further exploration of its mechanisms and long-term clinical studies are needed to clarify its meaning.

The primary pathological mechanism underlying acne is characterized by a complex interplay of factors, including androgen-induced excessive sebum production, abnormal differentiation and proliferation of keratinocytes within the hair follicle duct, dysregulated colonization of C. acnes, imbalances in the skin microbiome, and dysfunctions both in innate and adaptive immunity.10 Additionally, various risk factors, such as genetic predisposition and environmental triggers can influence the development of acne.11,12 Hormonal fluctuations, high-sugar diets, psychological stress, and improper skin care are environmental and behavioral factors that may serve as triggers or exacerbating elements, collectively promoting the onset and clinical progression of acne.13 Recent research into the molecular mechanisms of acne has identified novel key regulatory pathways: TREM2+ macrophages surrounding hair follicles exhibit impaired clearance of C. acnes,14 and the GATA6 transcription factor in keratinocytes is implicated in the dysregulation of hair follicle keratinization.15 The synergistic activation of the NLRP3 inflammasome and the formation of neutrophil extracellular traps (NETosis) intensify the inflammatory cascade within the hair follicle microenvironment.16 These findings enhance our understanding of the systemic characteristics of acne and suggest new avenues for developing targeted therapies that focus on specific immune pathways. Nevertheless, as an inflammatory condition with systemic implications, the mechanisms underlying acne require further comprehensive elucidation through longitudinal and experimental studies.

The management of acne necessitates consideration of various factors, including the severity of the condition, clinical subtype, involvement of specific anatomical areas, and the patient’s response to prior treatments. Current therapeutic approaches encounter significant clinical challenges, such as antibiotic resistance, low patient adherence, and high recurrence rates, underscoring the pressing need for advancements in personalized treatment strategies.17 These challenges emphasize the critical necessity for the development of drugs with novel mechanisms of action and the optimization of existing therapeutic strategies. Emerging technologies, including acne vaccines, targeted biologics, antimicrobial peptides, and exosomes, represent pioneering research directions that are propelling the treatment paradigm toward precision and enduring outcomes.

This review endeavors to furnish an exhaustive overview of the epidemiology, clinical manifestations, pathogenesis, diagnosis, management, and research frontiers pertaining to acne. It emphasizes recent advancements in understanding the pathological mechanisms underlying acne and examines the development of innovative treatment strategies and personalized medicine approaches.

Epidemiology

Prevalence and incidence

Acne, clinically referred to as acne vulgaris, is a chronic, relapsing inflammatory dermatological condition predominantly affecting the facial region, characterized by the involvement of hair follicles and sebaceous glands. Recognized as the eighth most prevalent disease globally, acne impacts over 9.4% of the global population, contributing to 0.29% of the total global disease burden. Its prevalence exhibits significant variation across different geographical regions, age groups, ethnicities, and socioeconomic statuses.18,19 Acne is intricately linked to hormonal changes that occur during puberty, with the highest incidence observed between the ages of 15 and 20, affecting approximately 85% of adolescents, and this condition can persist into adulthood and may exacerbate over time.18 Notably, maternal stress exposure during pregnancy has been associated with earlier onset of puberty in offspring in a dose-dependent manner.20 This may lead to premature hormonal fluctuations and subsequent early onset and persistence of acne. A cross-sectional survey conducted among Chinese university students revealed that the overall prevalence of moderate to severe acne was 10.4%.21 Research indicates that the prevalence of acne among adult women is approximately 10–12%, with a majority (89.8%) experiencing acne across multiple facial regions, including the cheeks, forehead, jawline, and temples. The severity of acne in these women is comparable to that observed during adolescence, often leading to significant anxiety regarding their appearance.22,23,24 From the perspective of racial susceptibility, although the prevalence of acne in the Chinese population is lower than that in the Caucasian population and adult acne is relatively uncommon, data reveal an increasing trend in the age-standardized prevalence, incidence, and disability-adjusted life years (DALY) rate in China.25,26 This trend is consistent with the global distribution of acne burden, where high-income countries typically encounter a greater burden of inflammatory skin diseases, such as acne, whereas low-income countries predominantly deal with infectious skin diseases. Notably, the incidence of acne in China is higher than that in most other Asian countries, ranking third after South Korea and Japan.27 This suggests that the modernization of a nation’s socioeconomic status, healthcare infrastructure, environmental conditions, and lifestyle factors may significantly outweigh the protective differences traditionally observed in racial genetics in the development of acne.

As one of the most prevalent dermatological conditions, acne and/or its resultant scarring can persist into adulthood. While not life-threatening, acne can impose substantial psychological and socioeconomic burdens on affected individuals.28,29,30 Recent studies indicate that acne adversely affects the quality of life in 90% of patients, with more than half experiencing mood disorders, such as anxiety, depression, and considerable emotional distress, potentially leading to suicidal ideation.31 Despite these impacts, a significant number of individuals with acne are reluctant to seek treatment and do not actively pursue effective therapeutic interventions, which is a critical factor in the progression of the condition.32 Consequently, the prevention and effective management of acne are of paramount importance.

The epidemiology and disease burden of acne vulgaris are shown in Fig. 1.

Fig. 1

Epidemiology and disease burden of acne vulgaris. a Global estimates of prevalent cases, age-standardized prevalence, DALYs and age-standardized DALY rate in 2023. b Global trends in age-standardized prevalence and DALY rates from 1990 to 2023. c Age- and sex-specific prevalence rates in 2023. d Regional differences in age-standardized prevalence rates in 2023 and their changes since 1990

Risk factors

Genetics

The substantial influence of genetic factors on acne susceptibility has been corroborated by numerous twin studies, which estimate heritability at 80%. A multitude of gene polymorphisms associated with acne susceptibility have been identified, underscoring the intricate nature of polygenic inheritance in this condition.33,34 Genes implicated in the pathogenesis of acne predominantly regulate sebaceous gland function, follicular keratinization, and tissue remodeling, encompassing several pivotal genes expressed in sebaceous gland cells, keratinocytes, and immune cells.35,36 Notably, genes such as WNT10A, LAMC2 and SEMA4B are integral to the genetic variation affecting skin barrier structure and the integrity of the follicular sebaceous unit, representing key mechanisms underlying genetic susceptibility to acne.37

Extensive genetic research has yielded more comprehensive evidence regarding the genetic determinants of acne. A recent genome-wide association study (GWAS) involving 20,165 individuals with acne identified 29 gene loci associated with an increased susceptibility to acne, predominantly enriched in pathways related to sebaceous gland function (WNT10A, TBX5, FGFR2), inflammation regulation (TNFRSF1A, IL1R1, STAT5A), and hormone metabolism (CYP11B1, CYP11B2). The study also suggested a genetic correlation between acne and chronic pain, particularly joint pain and headaches.38 Subsequent investigations have identified the Wnt/MAPK signaling pathway as a fundamental component of the genetic architecture of acne and have reported four novel acne susceptibility loci [11q12.2 (FADS2), 12q21.1 (LGR5), 17q25.3 (FASN), and 22q12.1 (ZNRF3-KREMEN1)].39,40 Additionally, FADS2, located at 11q12.2 and part of the FADS gene cluster, has been identified as a novel susceptibility site. Variations in this gene have been confirmed through Mendelian randomization studies to directly influence acne risk by modulating the metabolic levels of polyunsaturated fatty acids, such as DHA and LA.41 This discovery not only confirms the pathogenic significance of this site but also elucidates the genetic underpinnings of sebum fatty acid metabolism, which had previously been underappreciated, thereby establishing a strong connection between genetic loci and specific biological pathways.

Beyond the mechanisms previously discussed, recent research has highlighted the critical roles of various physiological processes, including oxidative stress, circadian rhythms, and immune regulation, in genetic susceptibility to acne. Specific genotypes of the glutathione S-transferase family genes (GSTT1, GSTP1-rs1695) and the tumor suppressor gene TP53 (rs1042522) have been significantly associated with an increased risk of developing acne vulgaris, indicating that the oxidative stress regulatory pathway is pivotal in the pathogenesis of acne.42 Moreover, the AG/GG genotype of the circadian rhythm gene CLOCK (rs1801260) has been significantly linked to an elevated risk of acne vulgaris, with this association being further intensified among night shift workers. This suggests a gene‒environment interaction between circadian rhythm disruption and acne development.43 In the context of tissue repair and immune regulation, the 3928 C/T polymorphism of GM-CSF, along with the polymorphic sites of MMP-1 (519 A/G) and TIMP-1 (372 C/T), not only influences the risk of disease development but is also intricately associated with the formation of postacne scars.44,45,46 Additionally, the palmitoyltransferase gene ZDHHC20 contributes to acne pathogenesis through methylation alterations at its regulatory site cg18095762.47 Genetic factors play a substantial role in determining the clinical manifestations and severity of acne. Research has demonstrated a strong positive correlation between the SREBF1 and IGF-1 signaling pathway genes and the occurrence of severe cystic acne and its severity.48,49,50

In conclusion, acne is characterized by a highly complex genetic architecture, with its pathogenesis involving not only the cumulative effect of multiple common risk alleles but also potentially significant regulation by major genes in specific clinical subtypes. These genetic insights collectively advance the understanding of acne toward a new phase of development, encompassing precision prevention based on risk prediction, early molecular diagnosis, and innovative targeted therapeutic strategies.

Environmental factors

In addition to genetic predispositions, a range of environmental and lifestyle factors, including air pollution, ultraviolet radiation exposure, diet, sleep patterns, behavioral habits, and stress, can contribute to the onset and predispositions of acne. Dietary composition is among the most prevalent triggers; notably, the Western diet, characterized by high levels of sugar, dairy products, and saturated fats, has been shown to significantly aggravate acne. This dietary pattern may underlie the persistently high prevalence of acne in Western countries.51

Research indicates that diets with a low glycemic index (GI) and low glycemic load (GL) can reduce concentrations of insulin-like growth factor-1 (IGF-1).52 Clinical trials have further demonstrated that adhering to a low-GL diet for 12 weeks can alleviate acne lesions by modifying the composition of sebum lipids.53 Conversely, consumption of high-GI foods, such as refined grains and sugary beverages, can rapidly elevate insulin and IGF-1 levels, thereby promoting acne development through enhanced androgen activity, sebaceous gland proliferation, and lipid synthesis.54 Additionally, chocolate consumption has been associated with the exacerbation of acne.55 Excessive consumption of sugary and carbonated beverages is a contributing factor to the development of acne.56 It is noteworthy that high-GI diets and obesity, often characterized by elevated BMI, share the core pathophysiological feature of hyperinsulinemia. Through pathophysiological alterations such as insulin resistance, hyperinsulinemia, and elevated androgen levels, these factors provide a continuous metabolic impetus for the initiation and progression of acne, thereby exacerbating the condition.57 Dairy products, particularly skim and low-fat milk, significantly elevate IGF-1 levels and further activate the mTORC1 signaling pathway, increase androgen receptor sensitivity, promote lipid production, and exacerbate inflammatory responses and microcomedone formation.58,59,60The Golgi protein GOLGA7B, through its regulation of palmitoyltransferase zDHHC5, influences CD36-mediated lipid metabolism and inflammation, thereby representing a novel pathogenic mechanism that links high glycemic index diets to the onset of acne.61

A high-fat diet has been associated with the development of hyperkeratosis of hair follicles and the induction of neutrophilic folliculitis in animal models62; conversely, the very low-calorie ketogenic diet (VLCKD) has demonstrated efficacy in ameliorating inflammatory skin conditions and mitigating acne triggers.63 Research indicates a correlation between the imbalance of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and the pathogenesis of acne.64,65 Targeted supplementation with omega-3 fatty acids derived from sources such as deep-sea fish and flaxseed has emerged as an effective nutritional intervention strategy. The mechanism of action involves the reduction of insulin-like growth factor 1 (IGF-1) and the inhibition of inflammatory leukotriene B4 synthesis. Dietary supplementation with omega-3 fatty acids or gamma-linolenic acid has been shown to significantly decrease the number of both inflammatory and noninflammatory skin lesions.66

Furthermore, antioxidant-rich diets have been found to substantially enhance the quality of life for individuals with acne.67,68,69 Probiotics, which influence the gut-skin axis, present a novel approach to the dietary management of acne by modulating immune inflammation and metabolic pathways. Research indicates that the oral administration of specific probiotic strains can modulate the expression of proinflammatory cytokines, enhance FoxO1 activity, and inhibit the IGF-1/mTOR pathway. This modulation contributes to the regulation of acne development from a multidimensional perspective, incorporating microbial, metabolic and immune factors.70,71

Smoking and alcohol consumption are associated with an increased risk of both developing and exacerbating acne. Evidence suggests that smoking elevates the risk of acne by promoting oxidative stress and local inflammation, with this effect being dose-dependent.72,73,74 Cigarette smoke can worsen acne lesions by inducing oxidative modification and degradation of the cholesterol receptor SRB1 in sebaceous gland cells, thereby disrupting cellular lipid metabolism homeostasis.75 Moreover, excessive alcohol consumption can lead to abnormal sebum secretion and immune dysregulation. Alcohol has been demonstrated to elevate the production of reactive oxygen species (ROS), which triggers oxidative stress and lipid peroxidation in the skin, ultimately resulting in skin barrier dysfunction.76,77 The nonoxidative metabolism of ethanol within the body, which results in the production of fatty acid ethyl esters (FAEEs), not only facilitates lipogenesis but also impairs mitochondrial oxygen consumption and ATP synthesis. This metabolic pathway exacerbates acne activity and diminishes the efficacy of treatment. Clinical studies have demonstrated a higher prevalence of acne among individuals with alcohol use disorders.78,79

Moreover, a recent study published in the BMJ suggests that extended mask usage can aggravate facial skin conditions such as acne, with health-care workers being particularly affected.80 Prolonged mask-wearing may alter the skin microbiome’s composition, fostering the growth of anaerobic bacteria and influencing acne development and through intricate interactions among pathogenic bacteria, helper bacteria, and inhibitory bacteria.81 Additionally, disruptions to the circadian rhythm may play a role in regulating acne development.82 Psychological stress is also recognized as a significant trigger for acne flare-ups and exacerbations,83 with mechanisms interactions among neural, immune and endocrine pathways.84 Many patients perceive stress as a major factor in the recurrence or worsening of acne, indicating that clinical practice should focus on assessing the psychosocial stress of acne patients, providing effective stress management strategies, and recommending professional psychological interventions when necessary.

Diagnosis, screening and classification

Acne is a chronic and heterogeneous dermatological condition characterized by multiple clinical subtypes, each with distinct anatomical distributions and disease progression trajectories, yet sharing common pathogenic mechanisms and often coexisting within the same patient.

Clinical subtypes and disease progression

Acne can be classified into several clinical types, including acne vulgaris (a mixed noninflammatory and inflammatory type, characterized by comedones, papules, and pustules), cystic acne (deep, tender nodules and cysts, prone to scarring), and acne conglobata (the most severe subtype, characterized by confluent inflammatory nodules, cysts, and sinus tracts, accompanied by significant tissue destruction and systemic symptoms). Acne vulgaris, the most prevalent form,85 presents a combination of noninflammatory and inflammatory lesions, such as comedones, papules and pustules, and typically manifests on the cheeks, forehead, chest and back regions associated with high sebum production.86,87 In its initial stages, acne is primarily marked by noninflammatory lesions. As the disease progresses, excessive keratinization of the hair follicle epithelium and sebum accumulation lead to the formation of closed comedones (whiteheads) and open comedones (blackheads).88 Cystic acne is characterized by the presence of deep, tender nodules and cysts, which are prone to scarring. The majority of individuals with acne experience mild to moderate symptoms, such as blackheads or redness, over a brief period.89 However, when C. acnes proliferates and triggers an inflammatory response, the condition can progress to inflammatory papules and pustules.90 If the inflammation extends deeper into the skin, it may result in the formation of deep, tender nodules and cysts, commonly referred to as cystic acne, which is susceptible to scarring.91 Scratching and squeezing due to itching can exacerbate acne lesions and potentially lead to permanent scarring.92 The incidence of acne fulminans is approximately 1%, and it can result in inflammatory nodules, ulcerative lesions, and scarring and pigmentation in later stages, which have a lasting impact on the patient’s appearance and psychosocial function. In clinical practice, personalized treatment for acne patients is frequently overlooked, leading to suboptimal adherence and reduced patient satisfaction.93,94 Conglobate acne represents the most severe subtype, predominantly affecting males, and is characterized by confluent inflammatory nodules, cysts, and sinus tracts. These lesions are notably large (1–5 cm is considered large, and greater than 5 cm is considered giant), often resulting in significant tissue destruction and accompanied by systemic symptoms. This form of acne is highly prone to leaving permanent scars upon healing.95,96,97,98 Despite the high prevalence of acne in clinical settings, achieving standardized management remains a considerable challenge within dermatology, underscoring the urgent need for continuous medical education and the promotion of standardized diagnostic and treatment protocols in this field.99,100

Clinical diagnosis and severity grading systems

Despite the existence of various international acne grading standards, considerable heterogeneity among studies arises from variations in clinical application and the inherent subjectivity of assessments. This represents a significant bottleneck impeding the evaluation of acne treatments and epidemiological research. An optimal acne grading scale should encompass dimensions such as lesion severity, lesion count, extent of involvement and disease duration.101,102 The Dermatology Quality of Life Index (DLQI), Pillsbury, and the Investigator’s Global Assessment (IGA) are currently the most widely utilized instruments for evaluating acne severity and its impact on patients’ health-related quality of life.103 Among these, the Pillsbury system is a traditional clinical assessment method that categorizes acne into four severity levels based on the type, number, and distribution of skin lesions. The IGA provides a swift grading of acne severity based on the clinician’s overall impression. In contrast, the DLQI employs a standardized multidimensional assessment approach to effectively quantify the symptom experience and psychosocial burden of acne patients, thereby serving as a crucial tool that bridges the gap between objective clinical assessment and subjective patient perception.104,105 To convert patients’ subjective experiences into quantifiable objective data, researchers have developed a patient self-assessment scale.106 A review of literature from the past two decades indicates an increased utilization of the Investigator Global Assessment (IGA), whereas the application of the LEEDS technique has declined. In North America, lesion counting and IGA are predominantly employed, while Europe favors the Leeds Revised Acne Garding System (LRAGS). Moreover, controlled experimental studies have shown a marked increase in the use of lesion counting, IGA and LRAGS.102,107 Establishing a minimum significant difference threshold for skin lesion counting could provide an objective benchmark for assessing treatment efficacy.108 The heterogeneity inherent in current assessment methodologies not only underscores the limitations of existing evaluation frameworks but also underscores the pressing need for the development of a standardized assessment system. It is noteworthy that most diagnostic tools have been predominantly developed with Caucasian skin as the reference point, thereby raising concerns regarding their efficacy in evaluating skin lesions and postinflammatory hyperpigmentation in individuals with darker skin. This discrepancy potentially exacerbates the diagnostic-treatment gap. Furthermore, the importance of patient-reported outcomes (PROMs) in the assessment of acne has gained increasing recognition in recent years.109,110 Research indicates that the primary health concerns of acne patients, in descending order of importance, include body image, appearance, life satisfaction, depression, and anxiety.111 This suggests that any comprehensive assessment system should incorporate patient-reported outcomes to better address these concerns.

AI-assisted diagnosis and digital assessment

Technological advancements have introduced promising solutions to existing challenges, notably through AI-assisted diagnostic technologies that significantly enhance the standardization of assessment methods. For instance, AI tools are currently utilized to enhance the clarity of blurry acne images in remote diagnostics, thereby improving diagnostic accuracy.112 The results from remote assessment platforms based on patient selfies, such as NORA, demonstrate a high degree of consistency with offline diagnoses.113 Additionally, three-dimensional image analysis and quantitative assessment of acne scars using reflective LED light have been developed.114 Furthermore, the system exhibits stable detection robustness under various imaging conditions, with recognition capabilities comparable to those of dermatologists.115 Collectively, these advancements establish a robust technical foundation for the development of new, objective, and reproducible standards for acne assessment.

Comorbidity

Acne is linked to a range of systemic comorbidities that can substantially affect a patient’s long-term health and quality of life.

Psychological burden and mental health comorbidities

Acne is linked to a range of systemic comorbidities that can substantially affect a patient’s long-term health and quality of life. Acne scars, particularly atrophic and hypertrophic scars, represent a common long-term complication of moderate to severe acne. These scars result from abnormal repair processes and an imbalance in extracellular matrix metabolism due to deep inflammation. Such permanent skin lesions are susceptible to causing significant social stigma, which imposes a considerable psychological burden on individuals with acne.116,117,118,119,120 Research indicates that the public often harbors negative attitudes and maintains social distance from individuals with severe acne, particularly those with severe acne and darker skin tones.121,122,123 Female patients with acne frequently experience heightened appearance-related anxiety.124 This combination of external stigma and internal appearance-related anxiety elevates the risk of developing depression and anxiety.125 Research indicates that the prevalence of major depressive disorder among individuals with acne is 18.5%, which is markedly higher than the 12.0% observed in the general population. Approximately 40.6% of adult acne patients express concerns regarding their mental health related to their appearance, with a suicidal ideation rate of 7.1%. Among adolescent acne patients, the rate of suicidal ideation is notably elevated at 22.5%, while the suicide attempt rate reaches 21.9%. Furthermore, these rates of suicidal ideation and attempts are exacerbated in patients experiencing severe acne.126,127,128,129 The underlying mechanisms may involve chronic inflammatory states and cytokine-mediated neuroimmune interactions.130 Additionally, it is important to recognize that acne medications, such as isotretinoin, can induce severe psychological issues, highlighting the necessity for vigilant management of mental health during treatment.131 Given that severe acne has a disability weight of 0.405, comparable to serious chronic conditions such as angina, it is imperative to combine effective treatment with psychological interventions.132 Consequently, incorporating cognitive behavioral therapy, mindfulness training, and social support into a comprehensive management plan is essential to enhance patients’ psychological resilience, improve treatment adherence, and mitigate anxiety and depression.133

Endocrine-metabolic comorbidities

From a metabolic perspective, acne frequently coexists with endocrine-metabolic disorders, including insulin resistance, obesity, and polycystic ovary syndrome (PCOS). As a prevalent clinical manifestation of PCOS, acne is closely associated with hyperandrogenaemia, affecting approximately 15% to 25% of individuals with PCOS.134 Research indicates that adolescent males with acne are at a heightened risk of developing insulin resistance (22% compared to 11%) and metabolic syndrome (17% compared to 9%) relative to their unaffected counterparts. Furthermore, these individuals face an increased likelihood of developing hyperinsulinemia or type 2 diabetes in the future.135 Recent studies also highlight a clustering of cardiovascular and metabolic risk factors linked to severe acne, suggesting that it may serve as an early indicator of potential metabolic health issues.136

Chronic inflammatory and treatment-associated comorbidities

Epidemiological research has indicated a modest increase in the incidence of inflammatory bowel disease (IBD) among patients with acne. While some suggest that the use of oral antibiotics or isotretinoin for acne treatment may elevate the risk of developing IBD, comprehensive epidemiological studies have not substantiated a causal relationship between these conditions.137,138 It is important to highlight that acne frequently emerges as an adverse effect during the administration of Janus kinase (JAK) inhibitors for IBD treatment, potentially exacerbating the psychological burden on patients and impacting their adherence to treatment regimens.139,140 Furthermore, there is a notable association between acne and hidradenitis suppurativa (HS), with a significantly higher prevalence of acne observed in HS patients than in the general population (15.2% versus 2.9%). The likelihood of developing acne in individuals with HS is 4.51 times greater than in the general population (95% CI: 4.40–4.63).137 This association suggests that these two conditions may share underlying pathophysiological mechanisms, such as abnormalities in the pilosebaceous unit, inflammation, and hormonal metabolism. Additionally, the rapid exacerbation of acne flare-ups can be accompanied by systemic symptoms, including fever, myalgia and arthralgia, as well as the appearance of diffuse papules, nodules and pustular lesions.141 Subsequent genetic analyses have indicated that acne fulminans and hidradenitis suppurativa (HS) may share a common etiology, potentially constituting a novel disease entity referred to as ASH syndrome.94 Prolonged antibiotic therapy can disrupt the skin’s microecological balance, resulting in a relative reduction in the abundance of C. acnes. This disruption may facilitate opportunistic skin infections, including gram-negative folliculitis.142

Global disease burden and integrated management

Acne represents a significant dermatological condition contributing to the global disease burden, accounting for 0.29% of all skin and subcutaneous diseases in terms of disability-adjusted life years (DALYs). It ranks second among skin diseases, surpassing other prevalent conditions such as psoriasis and urticaria.143 Although mortality directly attributable to acne is uncommon, associated mental health disorders, including anxiety and depression, as well as underlying metabolic comorbidities such as insulin resistance and polycystic ovary syndrome, can profoundly affect patients’ long-term health outcomes and quality of life. Consequently, the clinical management of acne should extend beyond the localized treatment of skin lesions to encompass a multidimensional, systematic approach. This approach should include comprehensive interventions, such as psychological support and comorbidity screening, to enhance patients’ physical, mental, and social health outcomes.

A summary of acne-associated comorbidities is shown in Fig. 2.

Fig. 2

Acne-associated comorbidities. Acne is associated with local skin manifestations, psychological burden, metabolic abnormalities, and chronic inflammatory comorbidities. Reported associations include depression or anxiety, suicidal ideation or suicide attempts, disability burden, insulin resistance, metabolic syndrome, polycystic ovary syndrome, hidradenitis suppurativa, and inflammatory bowel disease. Severe inflammatory presentations may also be accompanied by systemic symptoms such as fever, myalgia, arthralgia, diffuse papules or nodules, and pustular lesions. The figure was created with Figdraw (www.figdraw.com)

Mechanisms/pathophysiology

Overview

Over the past few decades, research into acne pathogenesis has advanced from the classical four-factor model—abnormal follicular keratinization, excessive sebum production, C. acnes expansion within an altered pilosebaceous microenvironment, and immune dysregulation—toward a more integrated view of acne as a lipid–immune–microbial–barrier–differentiation disorder. The dysregulation of the immune system plays a pivotal role in the pathophysiology of acne. The inflammatory response in acne is primarily driven by pro-inflammatory feedforward signal transduction originating from keratinocytes in the skin, in conjunction with the synergistic action of immune cells.11,31,144 Recent technologies, including single-cell RNA sequencing, spatial transcriptomics, lipidomics, and metabolomics, have further revealed cell-specific and spatially organized mechanisms underlying sebaceous gland differentiation, follicular inflammation, and tissue remodeling.145,146,147 The major skin immune mechanisms involved in acne pathogenesis are summarized in Fig. 3.

Fig. 3

Skin immune mechanisms of acne. a Altered pilosebaceous conditions, including increased sebaceous activity, follicular hyperkeratinization, barrier disruption, and C. acnes expansion, activate keratinocytes and sebocytes to release cytokines and chemokines, thereby initiating perifollicular immune cell recruitment. b Recruited neutrophils generate ROS, proteolytic granule contents, and NETs, which contribute to microbial control but may also damage the follicular wall, degrade the extracellular matrix, and amplify local inflammation. c Sustained microbial and lipid-derived stimulation reshapes macrophage responses, promoting inflammatory activation, TREM2⁺ macrophage accumulation, lipid metabolic reprogramming, impaired phagocytic clearance, and immune evasion mediated in part by C. acnes virulence factors such as CAMPs. d Acne-associated C. acnes strains, such as IA-2/HL043PA1, can activate dendritic cells to produce proinflammatory mediators, facilitating perifollicular immune cell recruitment and tissue injury. e Distinct dendritic cell subsets in acne lesions recognize C. acnes antigens, secrete effector cytokines, and connect innate immune activation with adaptive immune responses. f Antigen presentation to CD4⁺ T cells promotes inflammatory T-cell polarization, including Th1 and Th17 responses, which further enhance cytokine production, neutrophil recruitment, chronic inflammation, tissue remodeling, and scar formation. The figure was created with Figdraw (www.figdraw.com)

Skin barrier and sebaceous gland activity

The pilosebaceous unit is a metabolically active and immunologically responsive niche composed of sebaceous glands, follicular keratinocytes, lipids, proteins, resident immune cells and microbial communities.148 Hair follicles are surrounded by dendritic cells, Langerhans cells and other immune cells, making follicular targeting a potential strategy for local drug delivery and immunomodulation in acne.149,150 Lipidomics analyses have shown that individuals with acne exhibit increased relative abundances of odd-chain saturated fatty acids, squalene and certain monounsaturated fatty acids, whereas branched-chain free fatty acids and fatty alcohols are generally reduced.151 High-resolution spatial transcriptomics has further revealed a continuous lineage of human sebocytes from basal cells to terminally differentiated lipid-rich cells and identified infundibular keratinocytes as potential centers of inflammatory initiation. These findings provide a cellular and spatial basis for linking sebum production, follicular differentiation, barrier disruption and early inflammation in acne.145,152 Barrier impairment further increases follicular permeability, irritant susceptibility, and exposure to microbial or lipid-derived inflammatory stimuli, thereby facilitating the transition from comedogenesis to inflammatory lesions.

Sebaceous gland homeostasis is regulated by multiple endocrine, metabolic, and differentiation-related pathways, including androgens and other steroid hormones, retinoids, receptor tyrosine kinases such as the ErbB family, FGFR2, and insulin/IGF-1 receptors, as well as peroxisome proliferator-activated receptor γ (PPARγ), aryl hydrocarbon receptor (AhR), and Wnt signaling.153 PPARγ participates in sebocyte differentiation and lipid metabolic regulation through the PPARγ/LXRα/SREBP1 axis, thereby modulating androgen-induced lipid production, abnormal sebaceous cell proliferation and lipid components such as triglycerides and phosphatidylethanolamine.154 Among metabolic regulators, insulin/IGF-1 signaling provides a key mechanistic link between environmental factors, sebaceous gland activity, and inflammatory lesion formation. Activation of insulin/IGF-1 receptors can stimulate PI3K/Akt/FoxO1 and JAK2/STAT3 signaling, promoting sebaceous cell proliferation, lipid synthesis, and inflammatory responses.155,156,157 Functionally, this signaling axis may enhance sebocyte lipogenesis, increase sebum production, alter sebum composition, facilitate follicular obstruction, and create a lipid-rich microenvironment that supports C. acnes expansion and immune activation.

Additional regulatory pathways further refine sebaceous gland differentiation and lipid production. The NPY2R/NFATc1/DYRK1A signaling axis operates through NPY2R-mediated engagement of NPY5R and regulation of NFATc1 activity. Reduced DYRK1A activity enhances NFATc1 dephosphorylation and nuclear translocation, thereby activating transcriptional programmes associated with sebum synthesis and sebaceous differentiation.158 Lipid dysregulation also links metabolic and immune mechanisms in acne. Squalene can induce TREM2⁺ macrophage differentiation in vitro, and these macrophages exhibit reduced bactericidal capacity through impaired oxidase activity and oxygen free radical scavenging, thereby facilitating bacterial immune evasion and sustaining perifollicular inflammation. This squalene–TREM2⁺ macrophage axis highlights the interaction between lipid metabolism, immune regulation and microbial persistence in acne.14,159 In addition, elevated neuroendocrine hormones, such as growth hormone, thyroid hormone and prolactin, may further increase sebum secretion.160

These mechanisms provide a rationale for therapies targeting sebaceous gland activity and follicular delivery. Inhibition of androgen receptor (AR) or fibroblast growth factor receptor 2 (FGFR2) signaling can suppress sebum secretion, regulate keratinization of sebaceous gland ducts and modulate cell proliferation.161 A hyaluronic acid-functionalized nanozinc oxide (HA-ZnO) complex has been developed to target sebaceous glands, inhibit C. acnes, reduce excessive sebum production, modulate the local inflammatory microenvironment and support tissue repair.162 Future research should integrate molecular subtyping, lipidomic profiling, and targeted delivery systems to enable more precise and individualized regulation of sebaceous gland function. A summary of sebaceous gland activity, lipid dysregulation, and barrier-associated inflammation is shown in Fig. 4.

Fig. 4

Sebaceous Gland Activity, Lipid Dysregulation, and Barrier-Associated Inflammation in Acne Pathogenesis. a Upstream endocrine, metabolic, and differentiation-related pathways regulate sebocyte proliferation, lipid synthesis, sebum secretion, ductal keratinization, and inflammation. b Hair follicles are surrounded by immune cells and may serve as sites for follicle-targeted drug delivery and local immunomodulation. c, Acne-associated lipidomic alterations contribute to sebum dysregulation, follicular obstruction, C acnes expansion, and inflammatory amplification. d Squalene accumulation promotes TREM2⁺ macrophage differentiation, reduces bactericidal capacity, and links lipid metabolism with microbial persistence and inflammation. e Targeted strategies, including AR/FGFR2 inhibition and HA-ZnO nanocomplexes, aim to reduce sebum production, inhibit C. acnes, modulate inflammation, and support tissue repair. The figure was created with Figdraw (www.figdraw.com)

Host inflammation

Host inflammation in acne arises from the bidirectional interaction among follicular keratinocytes, sebocytes, altered lipids, microbial products, and recruited immune cells. Rather than being driven solely by immune activation or C. acnes colonization, acne-associated inflammation is initiated within the altered pilosebaceous microenvironment, where follicular hyperkeratinization, increased sebum production, lipid oxidation, and barrier impairment create permissive conditions for microbial expansion and inflammatory amplification.

A key early event is abnormal differentiation of the follicular infundibulum. Downregulation of the transcription factor GATA6 has been associated with follicular hyperkeratinization and aberrant sebaceous gland activity.15,163,164 This process is accompanied by obstruction of the follicular opening and increased expression of keratins, particularly keratin 1, 16 and 17, as well as filaggrin in the infundibulum of acne lesions, ultimately promoting microcomedone formation.165 These microcomedones retain sebum and generate a relatively anaerobic, lipid-rich environment that favors C. acnes expansion.

Excess sebum further contributes to inflammation not only by serving as a nutrient source for C. acnes but also through its bioactive lipid components. Oxidized lipids, such as squalene peroxide, can stimulate keratinocytes and sebocytes and promote inflammatory signaling. Activation of TLR2-related pathways can induce calcium influx in keratinocytes and promote the release of proinflammatory mediators, including IL-1β, IL-6, IL-8, and MCP-1.166,167 These mediators recruit neutrophils, monocytes/macrophages, and dendritic cells, thereby linking epithelial and lipid abnormalities to innate immune activation. In parallel, C. acnes virulence factors, including CAMP factors, can stimulate antimicrobial peptide and chemokine production, further promoting neutrophil recruitment and NETosis. When excessive, this response contributes to follicular wall rupture and lesion progression.168

As inflammation progresses, antigen-presenting cells, particularly dendritic cells, present C. acnes antigens through MHC-II molecules and promote CD4⁺ T-cell activation. Subsequent Th1 and Th17 polarization amplifies local inflammation through IFN-γ, TNF-α, IL-17A, IL-17F, and IL-22, which enhance macrophage activation, keratinocyte-derived antimicrobial peptide production, chemokine release, and further neutrophil recruitment.169 Therefore, host inflammation in acne should be understood as an integrated lipid–epithelial–microbial–immune circuit: nonimmune abnormalities initiate and shape inflammatory responses, while immune mediators feed back on sebocytes and keratinocytes to worsen lipid dysregulation, follicular obstruction, barrier damage, and tissue injury.

Immunity

Innate immunity

The innate immune response to acne is initiated by the recognition of cell wall components of C. acnes, such as peptidoglycan and lipoteichoic acid, by pattern recognition receptors (PRRs) located on the surface of host keratinocytes, sebaceous gland cells and resident immune cells.170 The Toll-like receptor 2 (TLR2), with the assistance of CD14, binds to pathogen antigens and recruits MyD88 via the Toll/Interleukin-1 receptor (TIR) domain. This interaction activates downstream IRAK kinases, subsequently triggering the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and the mitogen-activated protein kinase (MAPK) pathway. These pathways induce the release of inflammatory mediators, including interleukin-1 alpha (IL-1α), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), chemokine (C-C motif) ligand 2 (CCL2), and antimicrobial peptides such as human beta-defensin 2 (hBD2) and LL-37. These mediators further recruit neutrophils and macrophages to the site of infection, initiating an early inflammatory response. The aryl hydrocarbon receptor (AhR) functions as a critical regulatory node within this signaling network.171,172,173 Additionally, the ion channel factor transient receptor potential vanilloid 3 (TRPV3) can upregulate TLR2 expression in a p-FOSL1-dependent manner, thereby activating the NF-κB pathway, promoting inflammation in the sebaceous glands, and facilitating neutrophil aggregation. This process further releases various pro-inflammatory mediators, thereby perpetuating the inflammatory response.174

Under the combined influence of chemokines and proinflammatory mediators, there is a substantial recruitment of neutrophils and monocytes/macrophages to the pilosebaceous unit, initiating an early inflammatory response characterized by the infiltration of these immune cells. Concurrently, epidermal intrinsic-like lymphocytes, such as γδ T cells and invariant natural killer T (iNKT) cells, contribute significantly to early immune surveillance.175,176 C. acnes is capable of inducing NETosis in neutrophils, leading to the release of extracellular neutrophil traps (NETs), which further aggravate damage to the follicular wall and exacerbate inflammation.16,177 The recruited macrophages actively phagocytize C. acnes and concurrently release substantial quantities of ROS and matrix metalloproteinases (MMPs). This process induces lysosomal rupture and potassium ion efflux, subsequently activating the NLRP3 inflammasome. This activation promotes the maturation and release of caspase-1-dependent cytokines IL-1β and IL-18.178,179 C. acnes has the capacity to stimulate keratinocytes to synthesize TNIP1, which functions as a negative regulator of the NF-κB signaling pathway. This regulation inhibits the activation of the pathway and consequently restricts the production of downstream inflammatory mediators.180 Histone deacetylases HDAC8 and HDAC9 in keratinocytes play a pivotal role in maintaining innate immune tolerance to TLR antigen recognition. They achieve this by reducing the acetylation levels of histones H3K9 and H3K27 within the MAP2K3 promoter region.181 However, short-chain fatty acids, which are metabolic byproducts of C. acnes, can compromise host immune tolerance by inhibiting HDAC8/9 activity, thereby lifting the suppression of MAP2K.182

Moreover, contemporary technologies, including Seq-Well S³ single-cell transcriptome sequencing, have identified the presence of functionally diverse fibroblast subsets within acne lesions. These subsets play active roles in the regulation of inflammation and tissue remodeling. Certain subsets contribute to tissue repair and fibrosis by expressing genes related to matrix remodeling, such as matrix metalloproteinases (MMPs) and their inhibitors.183 Conversely, other fibroblast subsets, characterized by preadipocyte features, are activated upon Toll-like receptor 2 (TLR2) recognition of C. acnes. This activation initiates adipogenesis and concurrently leads to the production of ductin, thereby augmenting the local innate immune defence.184

In conclusion, the innate immune mechanisms involved in acne represent a complex network comprising microbial recognition, inflammasome activation, antimicrobial peptide release, immune cell recruitment, and signal transduction. This network not only underpins the subsequent initiation of adaptive immunity but also contributes significantly to the chronicity of acne and associated tissue damage when excessively or persistently activated. Consequently, interventions targeting critical components such as NLRP3, TLR2, NETosis, or specific antimicrobial peptides have emerged as highly promising therapeutic strategies.

Adaptive immunity

Within the inflammatory microenvironment generated by the innate immune response, antigen-presenting cells, such as dendritic cells, present C. acnes antigens to CD4+ T lymphocytes via the major histocompatibility complex MHC-II, thereby initiating the adaptive immune response. The local cytokine and chemokine milieu further shapes adaptive immune polarization in acne. CXCL8 secreted by sebaceous cells can recruit T cells and neutrophils and promote the release of IL-1β, IL-6, and transforming growth factor-beta (TGF-β), which, together with C. acnes, favor the differentiation of naïve CD4⁺ T cells toward inflammatory effector phenotypes.185

Naïve T cells predominantly differentiate into Th1 and Th17 effector subsets, which collectively serve as the primary drivers of acne inflammation. The Th1 response is characterized by the secretion of IFN-γ and TNF-α, which further activate macrophages and enhance their antigen-presenting capabilities. In contrast, the Th17 response is marked by the production of substantial quantities of IL-17A, IL-17F, and IL-22, which effectively induce keratinocytes to express antimicrobial peptides and chemokines at elevated levels.186 As an important link between innate and adaptive immunity, the IL-17/Th17 axis has been implicated in systemic inflammatory diseases and acne-associated inflammation.187,188,189 This inflammatory axis promotes follicular inflammation and tissue damage by enhancing inflammasome activation, neutrophil recruitment and keratinocyte-derived antimicrobial peptides and chemokines.169,190,191 Mechanistically, it can further amplify local inflammation through AIM2 induction and the upregulation of caspase-5 in keratinocytes.192,193

Recent research suggests that C. acnes can induce CD4⁺ Th17 cells to differentiate into an antibacterial subset (AM Th17) with direct bactericidal functions, which eliminate bacteria by secreting granzyme B and releasing T-cell extracellular traps (TETs).194,195,196 Overall, adaptive immunity in acne appears to shift toward a pro-inflammatory profile, with insufficient Th2/Treg-mediated regulation. Consistent with this profile, individuals with acne exhibit increased levels of pro-inflammatory mediators, such as IL-1α, IL-2, and VEGF, and reduced levels of anti-inflammatory mediators, including IL-4 and IL-10.197,198.

Treg cells located in hair follicles play a crucial role in regulating the proliferation and differentiation of hair follicle stem cells and maintaining local immune tolerance. They suppress excessive cutaneous inflammation through Foxp3 expression and IL-10 secretion. Dysfunction of these cells is therefore considered a potential mechanism underlying inflammatory immune diseases of the skin. TGF-β can induce the differentiation of Foxp3⁺ inducible Treg cells, thereby enhancing immune tolerance. Furthermore, therapeutic agents such as isotretinoin may exert part of their effects by promoting Treg function.199,200,201,202

Beyond T-cell responses, B cells also contribute to long-term tissue remodeling and scar formation in acne. Persistent B-cell infiltration and consequent irreversible downregulation of sebaceous gland lipid metabolism genes have been identified as critical mechanisms driving atrophic scar formation.117 The glycosylation state of the γ-secretase complex, particularly its subunit NCSTN, which is integral to the Notch signaling pathway, can modulate the development of marginal zone (MZ) B cells and B-1 B cells, as well as T-cell-independent antibody responses. This modulation influences local B-cell immune abnormalities and the progression of inflammation in acne.203,204

Together, the interaction between innate and adaptive immune mechanisms intensifies the inflammatory cascade and contributes to the chronicity of acne, pathological tissue remodeling, and scar formation. These insights provide a foundation for novel therapeutic strategies targeting the Th17/Treg balance, B-cell responses, and γ-secretase signaling.

Central immune cells

Keratinocytes and immune cells constitute a dynamic cutaneous immune network that maintains skin homeostasis and coordinates inflammatory responses during acne development. Immune cells comprise approximately 7% of the total skin cell population but account for nearly 50% of RNA expression. Following alterations in the pilosebaceous microenvironment, immune cell recruitment and functional remodeling link epithelial activation with acute inflammation, antigen presentation, persistent immune stimulation, and tissue remodeling. Neutrophil-enriched responses are associated with pustular inflammation, oxidative stress, follicular wall damage, and extracellular matrix degradation. Macrophage programs integrate microbial clearance, lipid handling, inflammasome activation, immune evasion, and repair-associated remodeling. Dendritic cell subsets connect local microbial sensing with antigen presentation and adaptive immune polarization. These cellular programs may provide lesion-stage-specific immune signatures and potential indicators of inflammatory severity, scarring tendency, relapse risk, and therapeutic response.205,206,207,208

Neutrophils

In the early stages of acne inflammation, neutrophils are among the major effector cells recruited to the pilosebaceous unit by C. acnes-associated signals and chemokines such as IL-8, IL-1β, and CXCL1.209,210 They contribute to antimicrobial defense through phagocytosis, ROS production, granule release and NET formation.210,211 However, excessive neutrophil activation can convert a protective response into tissue injury. ROS, histones, proteases, elastase, MMP-8, and MMP-9 released during degranulation and NETosis can damage the follicular wall, degrade the extracellular matrix, and amplify keratinocyte-derived chemokine production through NF-κB-related feedback loops. Impaired NET clearance, including DNase1-related defects, may further sustain inflammation and contribute to tissue destruction and scarring.16,177,212,213 Keratinocyte-derived exosomes can also induce NETosis through NF-κB/p38 MAPK signaling, while a high-fat diet may exacerbate neutrophil recruitment through the keratinocyte CXCL1–CXCR2 axis.62,214

Collectively, neutrophil-enriched inflammation is closely linked to pustular lesion formation, follicular wall disruption, and early extracellular matrix degradation. Excessive NETosis, ROS production, and CXCL1/CXCR2-mediated recruitment may further amplify local tissue injury, making these processes relevant markers of acute inflammatory progression and potential intervention points for limiting tissue damage while preserving antimicrobial defense.

Macrophage

Macrophages contribute to acne by integrating pathogen clearance, lipid metabolism, inflammasome activation, and tissue remodeling. Under physiological conditions, macrophages phagocytose microbes, process antigens, and participate in repair responses.215,216,217 In acne lesions, however, single-cell analyses have identified TREM2⁺ macrophages with high expression of lipid metabolism-related genes such as APOE and LPL and an M2-like transcriptional profile. These cells are associated with perifollicular inflammation, tissue damage and reduced C. acnes clearance, while GRN/SORT1 upregulation may contribute to bacterial immune evasion.14,147 Other macrophage states may also influence disease activity: TREM1 activation promotes M1-like inflammatory polarization, whereas increased TIM3⁺ M2 macrophages in severe acne may support chronic inflammation and tissue damage.218,219

At the signaling level, NF-κB is a central regulator of macrophage inflammatory responses and can be activated by C. acnes stimulation.220,221 Impaired Nrf2 signaling may promote oxidative stress, mitochondrial dysfunction, and NLRP3 inflammasome-mediated pyroptosis, thereby amplifying inflammation.222 Accordingly, inhibition of TLR2/TLR4/MyD88/NF-κB signaling and its downstream mediators, including TNF-α, IL-6, NO, and iNOS, has been shown to attenuate acne-related inflammation.172,223 C. acnes may also activate the cGAS–STING pathway and induce type I interferon responses through a nonclassical TRIF-dependent mechanism.224

Macrophage metabolism provides another layer of regulation. After bacterial phagocytosis, macrophages can use bacterial degradation products as metabolic substrates through the mTORC1–RagA axis, incorporating bacterial carbon sources and amino acids into glutathione and itaconate biosynthesis and supporting oxidative phosphorylation.225,226,227 Lysosomal degradation, cathepsins, ROS and autophagy are essential for bacterial killing and antigen presentation.228,229 Cathepsins also regulate macrophage polarization, TLR signaling, cytokine secretion, programmed cell death, and antibacterial immune functions, thereby contributing to macrophage homeostasis and inflammatory control.230,231,232,233,234 In addition, CAMP factors secreted by C. acnes can target macrophages, promote IL-8 release through TLR2 signaling, and modulate FcγR-dependent phagocytosis, caveolin-1 expression, IL-1β secretion, and immune escape.235 These macrophage-mediated responses are summarized in Fig. 5.

Fig. 5

Macrophage mechanisms in acne. After macrophages engulf C. acnes, they form acidified phagolysosomes with the participation of cathepsins, which, in conjunction with reactive oxygen species (ROS) and autophagy, achieve bacterial clearance and antigen exposure. Bacterial antigens are presented through the MHCII-TCR complex, activating T-cell-mediated adaptive immunity. Bacterial components activate the NF-κB and Nrf2 signaling pathways through TLRs, promoting the release of inflammatory mediators and regulating antioxidant responses. Excessive ROS production exacerbates oxidative stress, leading to sebum peroxidation. Simultaneously, the mTORC1-RagA signaling axis, based on degradation product sensing, is activated, driving macrophages to reprogram bacterial precursors such as carbon atoms and amino acids into biosynthetic pathways such as glutathione and itaconic acid and promoting oxidative phosphorylation to meet their bioenergy and antioxidant needs in the activated state. The figure was created with Figdraw (www.figdraw.com)

DCs

Dendritic cells (DCs) are professional pathogen-sensing and antigen-presenting cells that connect innate and adaptive immunity in acne.236,237 By recognizing C. acnes antigens and presenting them to CD4⁺ T cells through MHC-II molecules, DCs shape downstream T-cell responses, including regulatory, Th1-associated and Th17-associated polarization.238,239 Importantly, DC activation is influenced by C. acnes strain heterogeneity. Acne-associated strains, such as ribosomal type HL043PA1 and germline type IA-2, induce stronger pro-inflammatory cytokine production, including IL-1, IL-6, IL-15, and IL-17, whereas health-associated strains elicit weaker responses.240 Thus, DCs provide a mechanistic link between microbial strain diversity and host inflammatory outcome.

Single-cell sequencing has identified several DC populations in acne lesions, including CD1C⁺ DCs, Langerhans cells, and LAMP3⁺ DCs, with LAMP3⁺ DCs capable of producing CCL17 and promoting local IL-12 production.14 Additional inflammatory DC subsets include cDC1 cells marked by CLEC9A, IRF8 and WDFY4 and cDC2 cells marked by IRF4, SOCS2, SLCO5A1, CD1B and CD1E.183 cDC1 cells appear particularly relevant in acne.241 Activated EpCAM⁺CD59⁺Ly-6D⁺ cDC1 cells can regulate neutrophil recruitment, survival, and function at sites of C. acnes infection through VEGF-α production.237,242 HIF-α deficiency in cDC1 cells, which affects VEGF-α regulation, can attenuate C. acnes-induced inflammation by reducing immune cell infiltration and cDC1 activation.243

Together, neutrophils, macrophages, and dendritic cells form a coordinated immune-cell network that links follicular obstruction, microbial signals, lipid dysregulation, acute inflammation, adaptive immune activation, and tissue remodeling. Neutrophil-associated NETosis is closely related to pustular inflammation and early tissue damage, whereas macrophage lipid handling and inflammasome programs may contribute to persistent inflammation and scarring tendency. Dendritic cell antigen-presenting programmes further connect strain-specific microbial sensing with adaptive immune polarization and recurrent inflammatory activation. Integrating these immune signatures with single-cell, spatial, lipidomic, and clinical data may help define acne endotypes, improve risk stratification for scarring or relapse, and guide selective anti-inflammatory strategies that preserve host defense and microbial homeostasis.

C. acnes and microbial homeostasis

The skin microbiome is essential for maintaining barrier integrity, immune regulation, metabolic balance, and host defense. Its composition is shaped by ethnicity, age, skin physiology, environmental exposure, local biogeography, and host-specific regulatory mechanisms.244,245,246 The equilibrium of the microbial community is essential for preserving the skin’s physical barrier, modulating immune responses and metabolic processes and augmenting the host’s defense mechanisms.247,248 In sebaceous gland-rich areas such as the face and back, lipophilic Propionibacterium species, particularly C. acnes, predominate, whereas moist sites such as the axillae and elbows are enriched in Staphylococcus, Corynebacterium, and other bacterial and fungal taxa.249,250,251 This topographical distribution reflects both local skin biogeography and host-specific regulatory mechanisms.252 Importantly, dominant microorganisms such as C. acnes exhibit marked strain-level diversity, and their signaling responses, metabolic features, and immunomodulatory functions vary by anatomical site, allowing functional adaptation to distinct host microenvironments.253 The gut microbiota may also influence skin microbial and immune homeostasis through the gut–skin axis, providing a systemic perspective on acne pathogenesis.254

C. acnes, a prominent commensal bacterium of the skin and an opportunistic pathogen implicated in acne, possesses a genome comprising an approximately 2.5 Mbp circular chromosome with a G + C content of approximately 60%.255 C. acnes demonstrates a dual functionality: it can enhance the synthesis of skin lipids, such as triglycerides and ceramides, by activating PPARα receptors on keratinocytes, thus strengthening the skin barrier function256; conversely, the various effector factors it secretes can induce or exacerbate inflammatory responses. For instance, CAMP variants exhibit hemolytic activity, dermatan sulfate adhesin (DsA) can bind to fibrinogen, porphyrins possess pro-inflammatory potential and enzymes such as lipases, sialidases, and hyaluronidases can degrade host tissues.257 Additionally, C. acnes can secrete the extracellular polysaccharide PANG, facilitating biofilm formation, which enhances adhesion and confers biocide resistance.258

Metagenomic sequencing has elucidated variations in the genomic sequences of C. acnes strains between individuals with and without acne. These distinct strains not only express unique functional proteases but also elicit different host immune responses, thereby playing specific roles in the development and progression of the disease.259,260,261 For instance, strains isolated from susceptible skin exhibit rigid polysaccharide structures that specifically activate the IL-6/IL-17 pathway and induce hyperglycolysis in the host skin, thereby exacerbating inflammation.262 This suggests that genetic and functional heterogeneity at the strain level may be crucial in determining pathogenic potential. Single-locus sequence typing (SLST), a molecular typing method based on strain-specific markers, provides direct evidence supporting this notion. SLST has confirmed that the relative abundance of SLST types A, C, and F increases in acne lesions, while types H, K, and L decrease, suggesting a correlation between specific strains and disease states.263 Moreover, high-resolution spatial genomics studies have demonstrated that individual pores can function as independent ecological units, facilitating monolineage colonization of C. acnes through a neutral bottleneck effect.264,265 This finding elucidates the ecological basis for the coexistence of multiple strains on the skin surface from a microscopic perspective. This diversity and functional adaptability at the bacterial strain level not only sustain the homeostasis of the skin microbiome but may also contribute to disease development by affecting mechanisms such as colonization resistance and inflammation regulation.266,267 Furthermore, whole-genome sequencing has demonstrated that highly inflammatory IA-1 strains (corresponding to SLST type A), as identified through multilocus sequence typing (MLST), frequently harbor linear plasmids. These plasmid-bearing strains are capable of inducing more robust inflammatory responses in dermal fibroblasts, indicating that mobile genetic elements may play a significant role in modulating their pathogenicity.268 Additionally, different subtypes of C. acnes can modulate host immune phenotype and antibacterial activity by differentially regulating the Th17 response.195,269

The pathogenicity of C. acnes is primarily attributed to the secretion of various enzymes and virulence factors.270 Lipases catalyze the breakdown of sebum into free fatty acids, which not only supply nutrients to the bacteria but also contribute to mitochondrial damage and AMPK-mediated autophagy, thereby intensifying inflammation.271,272,273 Phospholipases are responsible for the hydrolysis of cell membrane phospholipids, leading directly to tissue damage.274 Enzymes such as hyaluronidase (HylA) and sialidase facilitate the degradation of the extracellular matrix and cell surface glycans, thereby compromising barrier structures. Notably, large hyaluronic acid fragments generated by HylA can trigger TLR2-dependent inflammatory responses, whereas the disaccharides produced by HylB exhibit anti-inflammatory properties. The selective inhibition of HylA offers a theoretical foundation for the development of targeted therapeutic interventions.275 In the context of protein and small molecule virulence factors, the CAMP factor stands out as the most prevalent core virulence protein among the protein virulence factors. It possesses hemolytic and cytotoxic properties, and in conjunction with the host’s acidic sphingomyelinase, it can exacerbate cell death. Additionally, ceramidinase, iron-acquisition proteins, and heat shock proteins contribute to tissue degradation and immune evasion.276,277,278,279 Porphyrins have been shown to activate the inflammasome by inducing potassium ion leakage in cells.280 Studies have reported that the colonization ability of C. acnes is attributed to its distinctive antioxidant protein, RoxP, which binds to heme, enabling the bacterium to withstand oxidative stress and thereby facilitating its pathogenic potential.281 Collectively, these findings suggest that C. acnes facilitates the development and progression of acne through the synergistic actions of enzymes and virulence proteins, thereby compromising the skin barrier and triggering immune inflammation.278,282

Building upon an enhanced comprehension of pathogenic mechanisms, therapeutic approaches for C. acnes are undergoing continuous refinement. High-resolution cryo-electron microscopy at 2.8 Å has elucidated the structure of the 70S ribosome in C. acnes, revealing the presence of a specific bS22/bL37 antimicrobial protein. The narrow-spectrum antibiotic sarecycline operates via a dual-site inhibitory mechanism, offering a structural foundation for the development of pathogen-specific treatments.283,284 Concurrently, genetic modification of C. acnes is emerging as a novel avenue for acne therapy. Advances in transformation systems and methylation strategies have facilitated its stable colonization and functional protein secretion in murine models, establishing a technical groundwork for in situ microbial therapy.285 The CAMP factor, recognized as a pivotal virulence protein, has been identified as a significant therapeutic target. Vaccine research targeting this factor has demonstrated potential in neutralizing its activity and impeding pathogenicity.235,276 Nonetheless, further elucidation of its molecular mechanism and interaction network with host factors is needed. The major virulence mechanisms of C. acnes are summarized in Fig. 6.

Fig. 6

Virulence mechanisms of C. acnes. a Major phylogenetic subtypes of C. acnes. b CAMP factors and their variants, through their inherent hemolytic activity and cytotoxicity, target macrophages and synergistically exacerbate membrane damage and death in target cells with host acid sphingomyelinase; lipases hydrolyze sebum lipids to provide nutrient sources and activate AMPK-mediated autophagy pathways. c Phospholipases hydrolyze cell membrane phospholipids, leading to tissue damage; DsA binds to host fibrin, mediating the inflammatory response; porphyrins induce potassium ion leakage in cells and activate inflammasomes; PANG forms biofilms, enhancing adhesion and resistance to bactericides; and the rigid polysaccharide structure of bacteria activates the IL-6/IL-17 pathway and triggers hyperglycolysis in the host skin. d Hyaluronidase (HylA) and sialidase degrade the extracellular matrix and cell surface glycans, disrupting cell structure and exacerbating host inflammation. The figure was created with Figdraw (www.figdraw.com)

Epigenetics

Epigenetic regulation is pivotal in the pathogenesis of acne, as it modulates gene expression without altering the underlying gene sequence through mechanisms such as DNA methylation, histone modification, and noncoding RNAs.43,286,287,288 Research has demonstrated that histone acetylation influences the expression of the key lipid synthesis transcription factor SREBP1 and its downstream targets FAS and ACCα, thereby modulating lipid synthesis in sebaceous gland cells.289,290 Multiomics analyses have identified abnormal DNA methylation patterns in acne lesions, revealing 11 key differentially expressed methylation genes, including PTPRC, CD86, IL1B and TNF, which are enriched in immune-related pathways.291,292 The X-linked histone demethylase UTX (KDM6A) has been shown to maintain enhancer activity through a noncatalytic mechanism, thereby positively regulating the retinoic acid signaling pathway and the differentiation processes of sebaceous glands and hair follicles.293 Additionally, several microRNAs (miRNAs) exhibit differential expression in acne, contributing to immune imbalance by targeting key molecules within inflammatory signaling pathways.294,295,296,297 For instance, miR-31 and miR-23b are involved in the regulation of processes such as inflammation, melanin production, and barrier repair, which influence the development of postacne pigmentation and erythema.298 Additionally, circular RNAs (circRNAs), including circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018167 have been identified as being aberrantly expressed in severe acne. These circRNAs contribute to disease progression by modulating inflammation, metabolism and immune responses, thereby highlighting their potential as biomarkers and therapeutic targets.299

Epigenetic mechanisms not only impact the host but also affect the ecological behavior of C. acnes. By employing epigenetic modifications such as DNA methylation, the susceptibility of different C. acnes strains to bacteriophages can be regulated. Strains possessing a complete restriction-modification system are capable of evading bacteriophage attacks, whereas those with defective systems are more susceptible to elimination. This presents a promising strategy for the selective eradication of pathogenic strains.300 In hypoxic and lipid-rich environments, the short-chain fatty acids produced by this bacterium can disrupt epidermal immune tolerance and enhance TLR2/TLR3-mediated inflammatory responses by inhibiting histone deacetylases HDAC8/9 in keratinocytes.182

Neuroimmunity

The neuroimmune regulatory network is also an important component of the pathophysiology of acne. Neurological factors, such as psychological stress, can activate the hypothalamic‒pituitary‒adrenal axis, leading to the release of cortisol and neuropeptides. This process induces the secretion of proinflammatory cytokines, including IL-6 and IL-1β, and activates the CRH-POMC-ACTH axis in the skin, thereby exacerbating inflammation.301,302 Sebaceous glands express various neuropeptide receptors, such as CRHR-1/CRHR-2 and melanocortin receptor 5 (MC5R), the latter being specifically expressed in differentiating sebaceous cells, where its antagonism can inhibit sebum production.303 Keratinocytes and immune cells establish a “neuroimmune-skin axis” through neuropeptide receptors.304 Upon detecting external stimuli such as bacterial infections or mechanical stress, this axis modulates local inflammation and immune responses via neuropeptide–receptor interactions and influences downstream T-cell-mediated adaptive immune responses.305 Additionally, this axis operates synergistically with the γδ T-cell-IL-3 pathway, wherein IL-3 derived from GD3 cells reduces the allergen response threshold through neuronal IL-3R/JAK2-STAT5 signaling. This process promotes neuropeptide release and T-cell immune responses, collectively regulating allergic sensitivity and pathological pruritus.306 Furthermore, C. acnes can stimulate keratinocytes, sebaceous gland cells, and immune cells to produce antimicrobial peptides and cytokines, such as IL-1β and TNF-α, via innate immune pathways such as TLR2/4 and the NLRP3 inflammasome. This activation subsequently recruits and activates Th1/Th17 lymphocytes, which collaboratively mediate inflammation and tissue damage around the hair follicle.307,308

In summary, epigenetic regulation and the neuroimmune network, through multilevel and multiaxis interactions, together form a complex regulatory system for acne pathogenesis, providing a crucial theoretical foundation for developing novel therapeutic strategies targeting these pathways.

Management

While acne is not directly associated with mortality, the facial lesions associated with the condition frequently induce appearance-related anxiety and contribute to psychological issues such as low mood, diminished self-esteem, and depression. These psychological impacts impose a substantial burden on both the physical and mental health of affected individuals, particularly adolescents.309 Current acne management spans a broad spectrum, from evidence-supported pharmacological therapies to adjunctive procedural and skincare-based interventions and further to emerging precision and preclinical strategies. These approaches differ markedly in clinical maturity, therapeutic targets, and routine applicability. However, treatment outcomes exhibit considerable heterogeneity owing to various factors, including geographical location, climate, ethnicity and dietary habits.310 This variability underscores the need for further research into the mechanisms underlying acne and the conduct of high-quality clinical trials to advance treatment strategies. In clinical practice, individualized treatment plans should consider acne type, lesion severity and distribution, scarring risk, patient tolerance and treatment adherence.311 The major therapeutic strategies for acne management, categorized according to pathogenic targets and disease severity, are summarized in Table 1.

Table 1 Concise overview of acne management strategies according to pathogenic targets and disease severity

Full size table

Drug therapies

The primary strategies for acne pharmacotherapy have traditionally focused on suppressing sebum production, eradicating bacteria, and mitigating inflammation. In response to the escalating global issue of antibiotic resistance, clinical practice has evolved from relying on antibiotic monotherapy toward combination regimens that pair antibiotics with nonantibiotic agents, particularly topical retinoids and benzoyl peroxide. Notably, combination therapy has been demonstrated to be more efficacious than monotherapy.312,313,314,315 It is important to highlight that etiological research indicates that C. acnes remains highly susceptible to doxycycline and minocycline, with a sensitivity rate of 100%, whereas resistance rates to erythromycin and clarithromycin have surpassed 55%.316 Consistent with this shift, the 2024 American Academy of Dermatology guidelines strongly recommend benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and combination topical regimens, while emphasizing the limitation of systemic antibiotic use and concomitant use of benzoyl peroxide to reduce antibiotic resistance. In two identically designed phase III randomized trials of sarecycline in patients aged 9–45 years with moderate-to-severe facial acne, IGA success at week 12 was 21.9% and 22.6% with sarecycline versus 10.5% and 15.3% with placebo, respectively, with low rates of gastrointestinal, vestibular and phototoxic adverse events.31,317 These findings underscore the significant challenges faced by antibacterial treatments and emphasize the necessity for updating clinical strategies and developing novel therapeutic approaches.

Currently, the first-line treatment for acne adheres to a tiered approach. Mild to moderate cases are primarily managed with a combination of topical retinoids, benzoyl peroxide (BPO), and azelaic acid. In contrast, moderate to severe or refractory lesions necessitate systemic interventions, such as oral tetracyclines, hormonal therapies, or isotretinoin. Oral tetracyclines combined with topical retinoids/BPO have demonstrated significant efficacy, but prolonged antibiotic exposure increases the risk of antimicrobial resistance.318 Oral isotretinoin remains the most effective systemic option for severe, nodulocystic, scarring or treatment-refractory acne; however, its use requires careful monitoring because of mucocutaneous dryness, cheilitis, xerosis, ocular dryness, lipid abnormalities, liver enzyme elevations and strict pregnancy prevention requirements owing to teratogenicity.31,319 Posttreatment relapse is also clinically relevant. A recent large cohort study of 19,907 isotretinoin-treated patients reported acne relapse in 22.5% and isotretinoin retrial in 8.2%, with higher cumulative dosage associated with lower risks of relapse and retrial.320 These findings highlight the need for adequate cumulative dosing, maintenance therapy, individualized retreatment decisions, and long-term follow-up, particularly in relapse-prone patients.

Given the limitations of long-term antibiotics and isotretinoin-related safety concerns, hormonal and sebum-targeted therapies provide important antibiotic-sparing options for selected patients. Spironolactone, which modulates androgen-driven sebaceous gland activity, is increasingly used in women with persistent, adult, truncal, or hormonally influenced acne.24,321,322,323,324 Long-term observational studies suggest sustained efficacy without increased cancer risk and potential reduction in antibiotic use.325,326,327 More recently, the SAFA trial, a pragmatic, multicenter, phase III, double-blind randomized trial in women with persistent facial acne, showed greater improvement with spironolactone than placebo, with a more pronounced difference at week 24 than at week 12.325,328 Therefore, spironolactone represents a useful nonantibiotic systemic option for appropriately selected women, although menstrual irregularities, breast tenderness, dizziness, and hyperkalemia risk in susceptible patients should be considered.

Both the American Academy of Dermatology and the Global Alliance for Improved Acne Outcomes advocate for the combined topical application of tretinoin acid and benzoyl peroxide (BPO) as an initial and long-term treatment strategy for severe acne.329 Retinoic acid is prone to oxidation and degradation by benzoyl peroxide (BPO), and both compounds are known to cause skin irritation.330 In two 12-week phase 3 randomized, vehicle-controlled trials, microencapsulated tretinoin 0.1%/benzoyl peroxide 3% cream produced statistically significant improvements in IGA success and reductions in both inflammatory and noninflammatory lesion counts compared with vehicle and was generally well tolerated, with application-site pain and dryness among the most common adverse events. This innovative approach significantly reduces degradation rates and the incidence of adverse skin reactions.331 In hormonal therapy, combined oral contraceptives are suitable for appropriately selected females of reproductive age, especially those with menstrual flares, clinical hyperandrogenism, or a concomitant need for contraception. Randomized trials of ethinyl estradiol/drospirenone-containing contraceptives have shown significant reductions in inflammatory and total acne lesion counts compared with placebo, although safety considerations, including thromboembolic risk, blood pressure, migraine history, smoking status and other contraindications, should be evaluated before use.332,333 In recent years, novel topical sebum inhibitors, such as olumacostat glasaretil (OG), have garnered considerable attention. OG reduces lipid synthesis in sebaceous glands by inhibiting acetyl-CoA carboxylase, a crucial rate-limiting enzyme in fatty acid synthesis, thereby significantly decreasing sebum secretion. A phase IIa multicenter, randomized, vehicle-controlled study suggested that OG 7.5% gel was well tolerated and showed preliminary efficacy in moderate-to-severe facial acne; however, subsequent development requires larger trials to optimize dosing and confirm efficacy and long-term safety.334,335,336 Additionally, clascoterone cream 1%, the first-in-class topical androgen receptor inhibitor approved for acne vulgaris in the United States in 2020, provides a local anti-androgen approach by competitively inhibiting androgen receptor signaling within the pilosebaceous unit, thereby reducing sebum production and inflammation while avoiding systemic anti-androgenic effects.337 In two phase III randomized, vehicle-controlled trials involving patients with moderate-to-severe facial acne, clascoterone achieved higher IGA treatment success and greater reductions in inflammatory and noninflammatory lesion counts than vehicle after 12 weeks, with low adverse event rates and local skin reactions generally comparable to vehicle.338 Furthermore, the prevention of postinflammatory atrophic scars is a crucial treatment objective and a significant parameter for assessing treatment efficacy.339

Beyond short-term trial-reported adverse events, long-term safety and potential systemic risks remain important considerations in acne pharmacotherapy. Available epidemiological studies have not established a significant association between benzoyl peroxide use and benzene-related cancers340,341; current evidence also does not support a significant association between isotretinoin and sexual dysfunction340 or a clear causal relationship between isotretinoin use and adolescent suicide attempts342; nor do current data support a clear causal relationship between isotretinoin and sexual dysfunction or adolescent suicide attempts.343,344 Nevertheless, these findings should be interpreted alongside established drug-specific risks, such as local irritation with topical agents, antibiotic-associated resistance and microbiome disruption, teratogenicity and laboratory abnormalities with isotretinoin, and endocrine or electrolyte-related adverse effects with hormonal therapies.

Physical therapies

Physical therapy is increasingly recognized as a valuable adjunct or alternative to pharmacological treatment for acne, particularly in cases where patients exhibit drug intolerance, poor compliance or experience significant adverse reactions.345,346 Among the various modalities, light and laser-based devices are pivotal in acne physical therapy due to their substantial therapeutic efficacy and prolonged effects. Currently, optical technologies extensively employed in clinical settings include visible light therapy, photodynamic therapy (PDT), intense pulsed light (IPL), pulsed dye laser (PDL), infrared lasers and the novel 1726 nm laser.347,348,349

Comedonal acne is frequently managed through comedo extraction surgery, which necessitates meticulous techniques to prevent further skin damage. This procedure is often complemented by anti-inflammatory or antibacterial medications. Additionally, cosmetic treatments and gel laser therapy have proved effective in addressing comedonal acne.350 Within the realm of phototherapy, PDT represents a targeted therapeutic approach that utilizes photosensitizers, such as aminolevulinic acid (ALA) and methyl aminolevulinate (MAL), to specifically target hair follicles and sebaceous glands, thereby being selectively absorbed by C. acnes. Under the illumination of a specific light source, the photosensitizing agent is transformed into porphyrin, initiating a photodynamic reaction that precisely targets and destroys the intended tissue. A meta-analysis involving 701 patients demonstrated that photodynamic therapy (PDT) is both safe and effective for treating moderate to severe inflammatory acne, achieving an average reduction of approximately 15.98% in inflammatory lesions. Notably, ALA-PDT, MAL-PDT, and LMB-PDT exhibited superior clinical outcomes.351 The innovative 1726 nm laser displays selective absorption properties for sebum, facilitating precise thermal damage to sebaceous glands.349 Additionally, home-use LED devices, which leverage the inhibitory and anti-inflammatory effects of red and blue light on C. acnes, have emerged as a significant option for at-home treatment.352 Research indicates that modified 5-aminolevulinic acid photodynamic therapy enhances the penetration and conversion efficiency of photosensitizers, offering benefits such as rapid onset of action and favorable tolerability in cases of moderate to severe acne.353,354 Blue LED light has been shown to regulate the metabolism and proliferation of human fibroblasts, thereby facilitating wound healing.355 Red light therapy is associated with a low incidence of adverse reactions, such as skin irritation, erythema and pigmentation, and is generally well tolerated.356 Additionally, radiofrequency technology employs electrical energy to excite plasma, which acts on the dermis to promote collagen regeneration and tissue remodeling, making it particularly effective for repairing late-stage acne scars.357 Fractional radiofrequency and microplasma radiofrequency devices are frequently used owing to their lower costs, faster healing times, absence of surgical contraindications and broader applicability than lasers.357

Beyond light energy, the synergistic effects of solid microparticle liposome (SLM) delivery,358 microneedles and ultrasound offer distinct advantages in the realm of physically enhanced transdermal delivery.359,360 For instance, DMT310, a natural powder formulation derived from the freshwater sponge Spongilla lacustris, can rapidly open stratum corneum channels, thereby facilitating the efficient delivery of active ingredients. The weekly application has demonstrated significant efficacy and high adherence in cases of moderate to severe acne.361 The quercetin-chitosan/polylactic acid (CSQC/PLA) bilayer nanofiber patch facilitates a 24 h sustained release of quercetin, thereby providing continuous antibacterial and anti-inflammatory effects, with a 94.4% inhibition rate against C. acnes.362 Sodium hyaluronate microneedle patches loaded with ZnTCPP@ZnO nanoparticles exhibit a dual mechanism of reactive oxygen species sterilization and zinc ion repair when activated ultrasonically.363 Biphasic self-locking microneedle patches enable the sequential and rapid release of antibacterial agents followed by sustained-release anti-inflammatory agents, allowing for precise sequential treatment.364 Eugenol-loaded hyaluronic acid dissolving microneedles, when combined with near-infrared light activation, achieve simultaneous deep antibacterial and localized anti-inflammatory effects.365 Collectively, these methodologies enhance the transdermal delivery efficiency and treatment precision of drugs through physical mechanisms, offering novel therapeutic strategies to circumvent antibiotic resistance.

Overall, light and laser-based physical therapy has evolved from an auxiliary role to an adjunctive/complementary part of comprehensive acne management. Its effects cover the entire pathological process, from inhibiting sebum secretion and anti-inflammatory and antibacterial effects to repairing scars. With a deeper understanding of the mechanisms of phototissue action and the continuous emergence of new wavelengths and technologies, this type of treatment provides more precise, efficient, and personalized new options for patients who do not respond well to or are intolerant of traditional drugs.

Chemical peeling therapies

Chemical peels represent an important adjunctive approach in acne management, frequently employing peeling agents such as salicylic acid, glycolic acid, and trichloroacetic acid for the management of mild to moderate acne. This minimally invasive procedure is gaining popularity among patients seeking minimally invasive cosmetic treatments.366 The mechanism of action involves the dissolution of intercellular adhesions, facilitating epidermal exfoliation and the unclogging of hair follicles, which alleviates follicular obstruction and dissolves microcomedones. Concurrently, controlled chemical exfoliation may promote dermal remodeling and collagen synthesis, thereby offering a dual benefit of treating active acne and ameliorating superficial scars.318 To enhance the stability and tolerability of salicylic acid, researchers have developed supramolecular salicylic acid (SSA) utilizing reversible noncovalent bonding technology. The sustained release properties and low irritation profile of SSA may improve tolerability and help restore skin microecological balance in acne patients.367,368 In parallel, the novel derivative SA-g-Alg, a graft of salicylic acid and sodium alginate, has undergone enhancements via molecular engineering. This advancement has resulted in a 30-fold increase in the stability of aqueous solutions while maintaining considerations of efficacy, safety and moisturizing properties, thereby demonstrating significant potential for clinical application.369 Notably, trichloroacetic acid-induced localized inflammatory responses have been effectively utilized to develop research models for postacne hyperpigmentation, indicating that chemical exfoliation techniques play a crucial role in modulating outcomes of postinflammatory hyperpigmentation.298 Furthermore, azelaic acid, retinol, and other topical skincare constituents are also recommended by dermatologists as adjunctive options in acne management.370

The clinical application of chemical peeling therapy is subject to several limitations. These include the necessity for multiple treatment cycles and the associated high costs. Posttreatment reactions commonly involve temporary erythema, burning sensations, and desquamation. Additionally, patients with certain skin types may experience persistent irritation or postinflammatory hyperpigmentation, resulting in considerable variability in treatment tolerance.371 Current research endeavors aim to optimize exfoliation protocols and enhance safety by implementing strategies such as reducing the concentration of peeling agents, extending treatment intervals, and incorporating soothing and reparative products. Furthermore, combined regimens integrating chemical peels with photodynamic therapy, topical medications, or other modalities are being explored to improve therapeutic efficacy in refractory acne.

Other therapies

Stress, dietary habits, smoking, and environmental factors significantly influence the pathogenesis of acne. The psychological impact of acne on adolescents is frequently underestimated, with feelings of inferiority and depression potentially exacerbating the condition. Consequently, psychological interventions are integral to comprehensive acne treatment. Numerous studies have established a correlation between acne and diet, indicating that high glycemic load (HGL) diets may enhance the activity of insulin-like growth factor 1 (IGF-1), promote the proliferation of keratinocytes and sebaceous cells, and stimulate androgen production, thereby worsening acne.372 Ultraviolet radiation can intensify inflammation, making sun protection a crucial strategy for preventing acne exacerbation. However, certain sunscreen ingredients, such as zinc oxide nanoparticles (ZnO NPs), may interact synergistically with C. acnes under pathological conditions, leading to increased lipid peroxidation, further damage to the skin barrier, delayed healing of skin lesions, and promotion of scar hyperplasia.373 Additionally, daily skincare practices, including the frequency of cleansing and the selection of cleansers and moisturizers, can influence acne progression. Acne typically requires 2-3 months of continuous treatment to assess its effectiveness, and different treatment combinations are needed depending on the individual.374

Clinical challenges in acne management

Currently available acne treatments differ substantially in evidence maturity, therapeutic positioning, and practical limitations. Established pharmacological therapies remain the most evidence-supported options for controlling active lesions, particularly in moderate-to-severe, scarring or refractory acne.31 However, clinical decision-making must balance lesion clearance with tolerability, antibiotic resistance, reproductive safety, laboratory monitoring, relapse prevention, scar risk, cost, and long-term adherence. Risk factor and comorbidity assessments should also be incorporated into individualized management. In patients with adult-onset, persistent, menstrual-flare, or treatment-resistant acne, screening for hyperandrogenism, polycystic ovary syndrome, menstrual irregularity, metabolic abnormalities, or medication-related triggers may guide the selection of hormonal or sebum-targeted therapies. Dietary patterns, smoking, alcohol use, occupational exposure, occlusive cosmetics, inappropriate skincare, psychological distress, and scarring risk should also be considered when integrating lifestyle intervention, adherence support, and treatment intensity.72,79 Antibiotic-sparing strategies are therefore central to contemporary management and include limiting systemic antibiotic duration, combining antibiotics with BPO, using topical retinoids for maintenance and considering hormonal or sebum-targeted therapies in appropriately selected patients.315,331 For patients at high risk of scarring, early control of deep inflammation and timely escalation to systemic or procedural therapy may be more important than prolonged sequential monotherapy.119,375 Physical procedures, chemical peeling and supportive skincare can improve inflammatory lesions, pigmentary sequelae, tolerability and cosmetic outcomes, but they generally function as adjunctive rather than replacement therapies and are limited by heterogeneous protocols, cost and patient-dependent responses.318 These differences highlight persistent gaps in treatment stratification, comparative effectiveness, relapse prevention, scar prevention, and long-term outcome assessment. These considerations also provide a framework for assessing emerging targeted and microbiome-based strategies: their clinical value should depend on whether they improve patient stratification, reduce antibiotic reliance, prevent relapse or scarring and enhance long-term tolerability and adherence.

Precision medicine therapies

Microbiome modulation therapies

Personalized modulation of the microbiome has emerged as a potential strategy for restoring skin microecological balance in acne. By supplementing beneficial microorganisms or their bioactive components, microbiome-based approaches may contribute to acne management through competitive inhibition of pathogens, immune modulation and skin barrier repair.376,377 Compared with conventional antibacterial therapies, these approaches are conceptually attractive because they aim to restore microbial homeostasis rather than broadly suppress bacterial populations. However, their clinical role remains less established than that of standard topical or systemic therapies, and their efficacy may depend strongly on strain selection, formulation stability, delivery route, and host-specific microbiome characteristics.

Topical application of beneficial bacteria, particularly lactobacilli, represents one of the main microbiome-directed strategies.378 Microcapsule formulations containing live lactobacilli have been reported to regulate the skin microbiome, reduce the relative abundance of C. acnes and Staphylococcus aureus and improve mild to moderate acne.379 Other probiotics, including members of the Lactobacillus genus, can inhibit skin pathogens and biofilm formation through the production of organic acids, showing antibacterial activity against C. acnes and Pseudomonas aeruginosa.380 These findings support the potential of topical probiotics as adjunctive therapy. Nevertheless, current studies vary considerably in probiotic strains, dosages, formulations, treatment duration, and clinical endpoints, making direct comparison difficult and limiting the generalizability of existing evidence.

Beyond live probiotics, microbiome-responsive materials and probiotic-derived delivery systems have been explored to improve selectivity and reduce disruption of commensal bacteria. For example, a pathogen-responsive piezoelectric heterojunction material can be activated by the respiratory metabolism of C. acnes, generating reactive oxygen species through an enhanced piezoelectric-photocatalytic effect and selectively eliminating the pathogen while preserving beneficial commensals.381 Similarly, an organic zinc delivery system generated by zinc-enriched Bifidobacterium longum CCFM1195 may exert anti-inflammatory and antioxidant effects by modulating the TLR2/IκBα/IKKβ pathway.382 These approaches represent a shift from nonspecific antibacterial therapy toward more selective microbiome-compatible interventions. However, most of these technologies remain at an early translational stage, and their long-term effects on microbial ecology, barrier function, and inflammatory relapse require further validation.

The gut–skin microbiome axis provides another rationale for systemic microbiome modulation.383 Individuals with acne often exhibit gut microbial alterations, including reduced abundance of functional probiotics and butyrate-producing bacteria.384,385,386 Omega-3 fatty acid supplementation has been reported to increase butyrate-producing bacteria and reshape the gut microbiota, potentially contributing to reduced acne-related inflammation.387 Oral administration of Lactobacillus rhamnosus may also improve insulin signaling -related gene expression in the skin, modulate gut microbiota and tryptophan metabolism, and promote the production of indole anti-inflammatory metabolites through AhR signaling.70,388 In addition, personal care products containing plant-derived ingredients, such as monoterpenes, myrtle, and Tripterygium wilfordii, may influence the skin microbiome by inhibiting C. acnes and increasing microbial diversity, thereby improving clinical symptoms and microecological imbalance.389,390,391,392 However, the causal relationship between microbiome changes and clinical improvement remains difficult to establish because diet, host metabolism, hormones, skincare practices, and inflammation may all influence microbial composition.

Overall, microbiome modulation offers a biologically plausible and potentially personalized strategy for acne management, especially for patients with recurrent inflammation, antibiotic resistance concerns, or intolerance to conventional therapies. Nevertheless, compared with established pharmacological treatments, the evidence base remains more heterogeneous and less mature. Key challenges include poor colonization of exogenous probiotics on the skin, substantial interindividual variation in baseline microbiota, limited standardization of probiotic strains and formulations, uncertain durability of response and safety concerns related to live bacterial preparations. Future studies should prioritize well-designed randomized trials, standardized microbiome and clinical endpoints, strain-specific efficacy assessment, long-term safety monitoring, and identification of patient subgroups most likely to benefit from microbiome-based interventions.

Acne vaccines

Traditional acne treatments, particularly long-term antibiotics and systemic retinoids, are limited by antimicrobial resistance, tolerability issues, relapse, and safety concerns. With advances in acne pathogenesis and the skin immune microenvironment, vaccine-based strategies have emerged as a potential approach to selectively target pathogenic C. acnes factors while preserving the commensal microbiota.

Virulence factors identified through whole-genome sequencing of C. acnes have provided candidate targets for acne vaccine development. The field has shifted from early inactivated whole-cell approaches toward subunit, peptide, and mRNA-based platforms targeting specific virulence factors, including CAMP factors, sialidase and hyaluronic acid lyase A (HylA).276 Among these, CAMP factors have attracted particular interest because they can damage host cell membranes and amplify inflammatory responses.393,394,395 Immunization strategies using recombinant antigens or monoclonal antibodies against CAMP factors have been shown in preclinical studies to induce neutralizing antibodies, reduce C. acnes-induced inflammation and interfere with bacterial pathogenicity.278,282 These findings provide a mechanistic basis for targeted immunotherapy, although their translation into clinically meaningful acne improvement remains to be established.

Several candidates have entered early clinical development. Sanofi has initiated a phase I/II trial of an investigational acne mRNA vaccine candidate in adults aged 18–45 years with moderate-to-severe acne. This study evaluates the safety, efficacy, and immunogenicity of up to three intramuscular injections across different dose levels, with long-term follow-up to assess durability and longer-term outcomes. In parallel, patent-based and preclinical vaccine strategies have explored C. acnes surface or virulence-associated antigens, including dermatan sulfate-binding adhesins DsA1/DsA2 and putative iron transporter protein (PITP).396 The recombinant CAMP factor protein vaccine, developed by WestVac Biopharma Co. Ltd. in collaboration with West China Hospital of Sichuan University, represents the first therapeutic vaccine specifically targeting the critical pathogenic element of the CAMP factor. This vaccine has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) of China, offering renewed hope to acne patients globally.397 In addition, the bivalent therapeutic mRNA vaccine JCXH-401 has received FDA clearance for clinical trials and is designed to elicit targeted antibody responses against inflammatory mediators produced by pathogenic C. acnes subtypes.398 These developments indicate that acne vaccine research is moving beyond proof-of-concept studies; however, published efficacy and long-term safety data from completed clinical trials remain limited. HylA-targeted vaccination represents another mechanistically selective strategy. A peptide vaccine targeting HylA, developed by researchers at the University of California, reduced inflammation in animal models by neutralizing bacterial hyaluronidase activity and suppressing downstream inflammatory pathways.275

However, acne vaccines remain investigational. Their potential advantages over antibiotics include pathogen-selective targeting, reduced antibiotic resistance pressure, and possibly longer-lasting disease control. However, key challenges remain, including antigen selection, C. acnes strain heterogeneity, preservation of the commensal microbiota, durability of immune protection, and the need for completed clinical trials demonstrating meaningful lesion reduction, relapse prevention, quality-of-life improvement, and long-term safety. These strategies are summarized in Table 2.

Table 2 Targeted therapy strategy for C. acnes

Full size table

Targeted biologics

Targeted biologics have attracted interest as potential options for severe, refractory, or syndromic acne because they can selectively modulate key inflammatory pathways. These agents exert potent and precise anti-inflammatory effects by selectively inhibiting key nodes within the acne inflammatory network. TNF inhibitors may be useful in selected severe inflammatory presentations, particularly isotretinoin-induced acne fulminans or acne associated with autoinflammatory conditions.399,400 Their potential benefit is thought to result from broad suppression of TNF-driven inflammatory signaling and downstream immune activation. Nevertheless, paradoxical acneiform eruptions have also been reported during anti-TNF therapy, indicating that their effects may be context-dependent rather than uniformly beneficial.

IL-17 inhibitors represent another biologically plausible strategy because IL-17-related pathways are involved in follicular inflammation, neutrophil recruitment, and keratinocyte activation. These agents have been more extensively studied and clinically applied in hidradenitis suppurativa and several systemic autoinflammatory diseases, where IL-17-mediated inflammation is more clearly established.401,402 However, evidence supporting IL-17 blockade in common acne vulgaris remains limited.

Furthermore, IL-1β, a pivotal cytokine in innate immunity and a fundamental component of the inflammatory pathway, remains a focal point in acne treatment research. Current strategies include direct neutralization of mature IL-1β or inhibition of upstream caspase-1 activity to reduce IL-1β production.179,403 Compared with TNF or IL-17 blockade, IL-1β-targeted approaches may be more closely aligned with early innate immune activation in acne; however, clinical validation remains insufficient.

Overall, targeted biologics may be most relevant for highly inflammatory, refractory, or syndromic acne phenotypes rather than routine acne management. Their potential advantages include pathway-specific anti-inflammatory effects and possible utility in patients who fail or cannot tolerate conventional therapies. However, their broader application is limited by insufficient randomized trial data, high cost, systemic immunosuppression, infection risk, paradoxical inflammatory reactions, and uncertainty regarding patient selection. Future studies should define which acne phenotypes are biologically suited for cytokine-targeted therapy and should evaluate efficacy, safety, relapse prevention, and long-term outcomes using standardized clinical endpoints.

Frontier preclinical research

In recent years, acne treatment research has increasingly moved beyond the discovery of single active ingredients toward the optimization of therapeutic delivery, selectivity, and tolerability. This shift reflects persistent limitations of conventional treatments, including poor stability, limited follicular penetration, local irritation, antibiotic resistance, and variable patient adherence. Functional nanomaterials, biomimetic carriers, antimicrobial peptides, exosomes, and bacteriophage-based platforms have therefore been explored to improve targeted delivery, controlled release, antimicrobial selectivity, and tissue repair.404

Natural products and nanoformulations

Natural products combined with nanodelivery systems represent an active area of acne research. Nanoformulations may improve the solubility, stability, follicular delivery, and local bioavailability of natural compounds, thereby potentially reducing irritation and improving therapeutic efficiency. For example, linoleic acid-encapsulated sinapic acid transferosomes have shown anti-inflammatory activity and enhanced dermal delivery without obvious irritation.405 A glycyrrhiza polysaccharide-based biomimetic nanoparticle system, MSN-NH₂-GGP@PDA, has been reported to enable pH-responsive release and sebaceous gland-targeted delivery, exerting anti-inflammatory effects through inhibition of the TLR2-MAPK/NF-κB pathway.406 In addition, Saposhnikovia divaricata may reduce C. acnes-induced oxidative stress and pyroptosis by activating Nrf2 signaling and suppressing the NF-κB/NLRP3 inflammasome axis.222 Structure-based screening has also identified citronellol, citral and related compounds as potential modulators of inflammation and barrier-related pathways through SPTBN1/SIPA1L1 regulation.407 Similarly, optimized delivery of natural retinoic acid derivatives may help regulate keratinocyte differentiation and cutaneous immune responses.408 Despite these advances, many studies rely on in vitro assays, animal models, or computational screening, and direct comparisons with standard acne therapies are limited. In addition, natural compounds often have complex compositions, variable batch quality, uncertain pharmacokinetics, and potential sensitization risks. Therefore, their translational value will depend on standardized formulation, validated mechanisms, dose‒response assessment, and well-designed clinical studies rather than mechanistic plausibility alone.

Exosomes

Exosomes, as pivotal mediators of intercellular communication, have emerged as a forefront research focus in the development of innovative acne therapies. This is attributed to their capacity to deliver diverse bioactive molecules and concurrently modulate multiple fundamental pathological aspects of acne, including sebum secretion, abnormal follicular keratinization and inflammatory response.409,410 Studies have indicated that the expression of miR-124-3p is markedly downregulated in the serum exosomes of patients with severe acne, influencing the pathogenesis and progression of acne by modulating the PI3K-Akt/mTOR and MAPK signaling pathways.294 Recent combined in vitro and clinical experiments have demonstrated that fibroblast exosomes induced by Scutellaria baicalensis, through the IRF3-IFN-β-IL-10/IL-22 axis and inhibition of PPARγ, significantly decreased sebum production and inflammation in induced acne within 10 days, thereby establishing a “lipid-immune” dual-regulation exosome strategy.411 Furthermore, adipose-derived stem cell exosomes (ADSC-Exos) have emerged as a promising cell-free therapeutic agent in regenerative medicine, exhibiting substantial efficacy in accelerating chronic wound healing and promoting skin regeneration.412 The therapeutic appeal of exosomes lies in their ability to coordinate lipid metabolism, immune regulation, and tissue repair. However, their application in acne remains exploratory. Major barriers include heterogeneity of exosome sources, isolation and purification methods, cargo variability, dose standardization, storage stability, biodistribution, and safety concerns such as unwanted immunomodulation or pro-fibrotic effects. Moreover, current evidence does not yet establish whether exosomes offer advantages over existing topical or procedural therapies. Future studies should define standardized production criteria, active cargo components, delivery routes, and clinically meaningful endpoints such as lesion reduction, scar prevention, and relapse control.

Antimicrobial peptides

Antimicrobial peptides are attractive candidates for acne therapy because they can disrupt bacterial membranes, interfere with biofilms and exert anti-inflammatory effects with a theoretically lower propensity for resistance than conventional antibiotics.413 The tryptophan-containing peptide I4WL5W disrupts bacterial membranes and biofilms and shows anti-inflammatory activity.414 Rationally designed pH-responsive peptides can be activated in acidic microenvironments, allowing selective antibacterial activity and potential synergy with antibiotics.415 Other engineered peptides, such as DAP-7 and DAP-10, target C. acnes, including drug-resistant strains, and reduce bacterial proliferation and proinflammatory mediator expression in vitro and in vivo.307 Natural peptides such as CEN1HC-Br, derived from green sea urchins, display antibacterial activity superior to clindamycin in experimental models and reduce inflammation through downregulation of TLR2-mediated signaling.416 Morosiderin and temporin-1Dra also show inhibitory and anti-inflammatory effects against C. acnes in preclinical studies.417 In addition, PD-DP-008, a peptide drug candidate derived from frog skin secretions, has received approval from the Center for Drug Evaluation of the National Medical Products Administration to enter phase I clinical trials, following preclinical evidence of activity against drug-resistant C. acnes.418

Compared with traditional antibiotics, antimicrobial peptides may offer broader mechanisms of bacterial killing and reduced resistance pressure. Nevertheless, their translation is not straightforward. Peptides may be limited by proteolytic instability, short residence time in follicles, formulation challenges, potential cytotoxicity or irritation, high production costs, and uncertain pharmacodynamics in human skin. Importantly, most efficacy claims remain based on preclinical models, and superiority over established agents such as benzoyl peroxide, retinoids or topical antibiotics has not been demonstrated in large clinical trials. Therefore, antimicrobial peptides are best viewed as promising anti-C. acnes platforms that require rigorous clinical validation, especially for drug-resistant or antibiotic-intolerant acne.

Materials and delivery system innovation

Innovative materials and drug delivery systems aim to improve local drug retention, follicular targeting, controlled release, and barrier repair in acne therapy. For example, ZnO/PVA composite fibers prepared by centrifugal spinning and vapor-phase infiltration provide a stable antibacterial platform.419 Biomimetic mineralization-fabricated hyaluronic acid-stabilized nano-ZnO (HA-ZnO) has been reported to combine sebaceous gland targeting, selective antibacterial activity, and skin repair, with its safety and efficacy evaluated in human clinical trials.162 In addition, the dendritic macromolecule-based isotretinoin delivery system 13cRA-D has shown improved skin penetration and site-specific drug release.420

Dosage-form innovation has also expanded the functional design of topical anti-acne therapies. Tea tree oil (TTO)-loaded Pickering emulsions incorporated into chitosan hydrogels can provide sustained antibacterial release while supporting damaged skin barrier repair.421 Similarly, thyme oil (THO)-loaded PLGA nanoparticle hydrogels have been developed as acne dressings that combine biocompatibility, antimicrobial activity and local therapeutic delivery.422

These systems illustrate how carrier design may integrate antibacterial, anti-inflammatory and repair-promoting functions within a single topical platform. However, delivery innovation does not necessarily imply clinical superiority. Key translational challenges include formulation stability, batch reproducibility, material biocompatibility, degradation products, follicular accumulation, long-term safety, cost-effectiveness, and regulatory feasibility. Future studies should move beyond proof-of-concept formulation design and include comparative clinical trials assessing lesion reduction, tolerability, adherence, relapse, and patient-reported outcomes.

Bacteriophage therapies

Bacteriophage-based therapy has attracted attention as a precision antibacterial strategy for acne because it may selectively target C. acnes while minimizing disruption of commensal microorganisms.423 Experimental studies have shown that the bacteriophage φPaP11-13 can alleviate acne-like lesions by inhibiting PI3K/Akt signaling and promoting keratinocyte apoptosis.424 Localized phage therapy has also been reported to lyse C. acnes and reduce neutrophil chemokine expression, thereby attenuating inflammation in animal models.425 In addition, the N-terminal functional domain of phage lysozyme, generated by recombinant DNA technology, exhibits greater species specificity than the full-length protein and may serve as a potential antibiotic-sparing antibacterial approach.426

These findings suggest that bacteriophages and phage-derived proteins may provide a more selective strategy for targeting pathogenic C. acnes and modulating local inflammatory responses. However, phage therapy remains at an early translational stage in acne. Key challenges include C. acnes strain heterogeneity, narrow phage host range, potential phage resistance, limited delivery into pilosebaceous follicles, immune neutralization, formulation stability, and regulatory complexity. In addition, the inflammatory consequences of rapid bacterial lysis require careful evaluation, as the release of bacterial components could theoretically exacerbate local inflammation. Therefore, bacteriophage-based therapies should currently be regarded as promising but unproven approaches that require standardized phage selection, safety assessment, resistance monitoring, and controlled human trials. These emerging strategies are summarized in Table 3.

Table 3 Other innovative strategies for acne treatment

Full size table

Conclusions and perspectives

Acne vulgaris is a common but biologically complex inflammatory disease of the pilosebaceous unit. Its development cannot be fully explained by any single factor, such as increased sebum production, follicular hyperkeratinization, C. acnes overgrowth, or immune activation. Instead, current evidence supports a more integrated model in which genetic susceptibility, hormonal and metabolic signals, sebaceous lipid composition, microbial ecology, environmental exposures and host immune responses interact dynamically within the follicular microenvironment. In this context, C. acnes should not be regarded simply as an external pathogen. As a dominant commensal of sebaceous skin, it may contribute to skin homeostasis under physiological conditions, whereas specific strains, virulence factors, biofilm formation, altered lipid metabolism, and dysregulated host responses can shift this relationship toward inflammation. This dual role of C. acnes partly explains why broad antibacterial strategies are often insufficient and why acne tends to relapse after treatment withdrawal. Therefore, a central challenge in acne research is to define how homeostatic host-microbe interactions become pathogenic and how this transition can be prevented or reversed.

The clinical burden of acne also extends beyond visible inflammatory lesions. Acne frequently affects adolescents and young adults during psychologically vulnerable periods, and persistent or severe disease may lead to scarring, postinflammatory hyperpigmentation, anxiety, depression, and reduced quality of life. In adult patients, especially women with persistent or recurrent acne, endocrine and metabolic factors such as hyperandrogenism, insulin resistance, obesity, and polycystic ovary syndrome should be considered. These observations suggest that acne management should not be limited to short-term lesion clearance. A more comprehensive strategy should include assessment of disease phenotype, scarring risk, relapse tendency, psychological burden, lifestyle factors, skincare practices, and potential systemic comorbidities. Such an approach may help clinicians select treatment intensity more appropriately and avoid prolonged ineffective therapy, particularly in patients with refractory, recurrent, truncal, nodulocystic, or scar-prone acne.

Current therapies remain effective for many patients, but important limitations persist. Topical retinoids, benzoyl peroxide, antibiotics, hormonal agents, isotretinoin, physical therapies, and chemical peeling therapies all have defined clinical roles, yet they differ in efficacy, tolerability, cost, convenience, and long-term safety considerations. Increasing concern about antibiotic resistance has made antibiotic-sparing regimens a major priority. At the same time, irritation from topical drugs, adherence difficulties, pregnancy-related restrictions, laboratory monitoring for systemic therapies, and relapse after discontinuation continue to affect real-world outcomes. Procedural therapies and novel delivery systems may improve selected aspects of acne management, including inflammatory lesion control, scar repair, drug penetration, and patient adherence, but their protocols and long-term comparative benefits remain insufficiently standardized. Thus, future clinical studies should place greater emphasis on practical outcomes, including relapse prevention, scar prevention, tolerability, adherence, microbiome preservation, and patient-reported benefit, rather than relying only on short-term reductions in lesion counts.

Mechanistic studies will be essential for moving acne treatment toward more precise intervention. Single-cell sequencing, spatial transcriptomics, metagenomics, lipidomics, metabolomics, and proteomics are beginning to reveal the cellular and molecular heterogeneity of acne lesions. These approaches may clarify how sebocytes, keratinocytes, macrophages, dendritic cells, neutrophils, T cells, C. acnes strains, and other commensal microorganisms interact in different lesion types and disease stages. In particular, the metabolic and immune states of local macrophages, the composition of sebaceous lipids, the strain-level diversity of C. acnes, and the balance between inflammatory and repair responses deserve further investigation. Future work should also distinguish causal disease drivers from secondary inflammatory changes. Identifying reliable biomarkers for treatment response, relapse risk, scarring tendency, and microbiome status would provide a foundation for patient stratification and individualized therapy.

Emerging therapeutic strategies are now expanding the conceptual boundaries of acne treatment. Microbiome modulation, antimicrobial peptides, bacteriophage-based approaches, exosome-related therapies, smart delivery materials, sebum-targeted agents, biologics, and vaccines all represent attempts to move beyond nonspecific antibacterial or anti-inflammatory treatment. Among these, strategies targeting C. acnes virulence factors, including CAMP factors, are particularly interesting because they may reduce pathogenic inflammation without completely eliminating commensal bacteria. However, most of these approaches are still at an early translational stage. Their future value will depend on whether they can demonstrate clear advantages over established therapies in controlled clinical studies, especially in terms of durability, safety, cost-effectiveness, and suitability for long-term management. Ultimately, the goal of acne treatment should be to restore a stable pilosebaceous microenvironment, reduce recurrence and scarring, minimize unnecessary antibiotic exposure, and improve both skin-related and psychosocial outcomes. Continued collaboration among dermatologists, immunologists, microbiologists, pharmacologists, and bioengineers will be necessary to translate these mechanistic insights into clinically useful, patient-centered therapies.

References

  1. Evaluation of the prevalence, risk factors, clinical characteristics, and burden of acne scars among active acne patients in Brazil, France, and the USA. J. Am. Acad. Dermatol. 76, AB132 (2017).

  2. Greydanus, D. E., Azmeh, R., Cabral, M. D., Dickson, C. A. & Patel, D. R. Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life. Dis. Mon. 67, 101103 (2021).

    Article  PubMed  Google Scholar 

  3. Rao, A., Douglas, S. C. & Hall, J. M. Endocrine Disrupting Chemicals, Hormone Receptors, and Acne Vulgaris: A Connecting Hypothesis. Cells 10, 1439 (2021).

  4. Nagpal, N., Gordon-Elliott, J. & Lipner, S. Comparison of quality of life and illness perception among patients with acne, eczema, and psoriasis. Dermatol Online J. 25, 13030 (2019).

  5. Haroon, M. Z. et al. Quality Of Life And Depression Among Young Patients Suffering From Acne. J. Ayub Med Coll. Abbottabad 31, 436–440 (2019).

    PubMed  Google Scholar 

  6. Ip, A. et al. Young people’s perceptions of acne and acne treatments: secondary analysis of qualitative interview data. Br. J. Dermatol 183, 349–356 (2020).

    Article  CAS  PubMed  Google Scholar 

  7. Chrzaszcz, M. et al. Extracts from Cephalaria Uralensis (Murray) Roem. & Schult. and Cephalaria Gigantea (Ledeb.) Bobrov as Potential Agents for Treatment of Acne Vulgaris: Chemical Characterization and In Vitro Biological Evaluation. Antioxidants (Basel) 9 (2020).

  8. Lee, W. et al. Interrupting an IFN-gamma-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne. Ann. Rheum. Dis. 83, 787–798 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kridin, K. & Ludwig, R. J. Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study. J. Am. Acad. Dermatol 88, 824–830 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Melnik, B. C. Acne vulgaris: The metabolic syndrome of the pilosebaceous follicle. Clin. Dermatol 36, 29–40 (2018).

    Article  PubMed  Google Scholar 

  11. Harper, J. C. Acne vulgaris: What’s new in our 40th year. J. Am. Acad. Dermatol 82, 526–527 (2020).

    Article  PubMed  Google Scholar 

  12. Cruz, S., Vecerek, N. & Elbuluk, N. Targeting Inflammation in Acne: Current Treatments and Future Prospects. Am. J. Clin. Dermatol 24, 681–694 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gonzalez-Mondragon, E. A. et al. Acne and diet: a review of pathogenic mechanisms. Bol. Med Hosp. Infant Mex. 79, 83–90 (2022).

    PubMed  Google Scholar 

  14. Do, T. H. et al. TREM2 macrophages induced by human lipids drive inflammation in acne lesions. Sci. Immunol. 7, eabo2787 (2022).

    Article  CAS  PubMed  Google Scholar 

  15. Oules, B. et al. Contribution of GATA6 to homeostasis of the human upper pilosebaceous unit and acne pathogenesis. Nat. Commun. 11, 5067 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kim, H. J. et al. NLRP3 inflammasome activation and NETosis positively regulate each other and exacerbate proinflammatory responses: implications of NETosis inhibition for acne skin inflammation treatment. Cell Mol. Immunol. 21, 466–478 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Liu, Y. et al. Self-Driven, Stretchable Drug Delivery Electronics for Acne Treatment. ACS Nano 19, 31740–31752 (2025).

    Article  CAS  PubMed  Google Scholar 

  18. Chen, H. et al. Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Br. J. Dermatol 186, 673–683 (2022).

    Article  CAS  PubMed  Google Scholar 

  19. Deng, J. et al. Global pattern, trend, and cross-country health inequality of adult acne aged 25 + years from 1990 to 2021, a comprehensive analysis for global burden of disease and global dietary database. J. Health Popul Nutr. 44, 238 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gaml-Sorensen, A., Brix, N., Henriksen, T. B. & Ramlau-Hansen, C. H. Maternal stress in pregnancy and pubertal timing in girls and boys: a cohort study. Fertil. Steril. 122, 715–726 (2024).

    Article  PubMed  Google Scholar 

  21. Zhu, L. et al. Prevalence of acne in Chinese college students and its associations with social determinants and quality of life: a population-based cross-sectional study. Chin. Med J. (Engl.) 134, 1239–1241 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).

    Article  Google Scholar 

  23. Jankowski, M. & Goroncy, A. Anatomical variants of acne differ in their impact on social perception. J. Eur. Acad. Dermatol Venereol. 38, 1628–1636 (2024).

    Article  CAS  PubMed  Google Scholar 

  24. Barbieri, J. S. et al. Patient Perspectives on the Lived Experience of Acne and Its Treatment Among Adult Women With Acne: A Qualitative Study. JAMA Dermatol 157, 1040–1046 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Shen, Y. et al. Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities. Acta Derm. Venereol. 92, 40–44 (2012).

    Article  PubMed  Google Scholar 

  26. Wang, Y., Xiao, S., Ren, J. & Zhang, Y. Analysis of the epidemiological burden of acne vulgaris in China based on the data of global burden of disease 2019. Front Med (Lausanne) 9, 939584 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Urban, K. et al. Burden of skin disease and associated socioeconomic status in Asia: A cross-sectional analysis from the Global Burden of Disease Study 1990-2017. JAAD Int 2, 40–50 (2021).

    Article  PubMed  Google Scholar 

  28. Hagenstrom, K., Muller, K., Klinger, T., Stephan, B. & Augustin, M. Epidemiology and Healthcare of Juvenile and Late-Onset Acne: Claims Data Analysis. Dermatol Ther. (Heidelb.) 14, 3017–3031 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhu, Z. et al. Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis. Br. J. Dermatol 192, 228–237 (2025).

    Article  PubMed  Google Scholar 

  30. Fabbrocini, G., Cacciapuoti, S., Monfrecola, G. J. D. & therapy. A qualitative investigation of the impact of acne on health-related quality of life (HRQL): development of a conceptual model. Dermatol Ther (Heidelb). 8, 85–99 (2018).

  31. Reynolds, R. V. et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol 90, 1006 e1001–1006.e1030 (2024).

    Article  Google Scholar 

  32. Bray, J. K., Masicampo, E. J. & Feldman, S. R. The bandwagon effect increases acne treatment willingness in teenagers. J. Am. Acad. Dermatol 83, 1172–1174 (2020).

    Article  PubMed  Google Scholar 

  33. Mina-Vargas, A. et al. Heritability and GWAS Analyses of Acne in Australian Adolescent Twins. Twin Res Hum. Genet 20, 541–549 (2017).

    Article  PubMed  Google Scholar 

  34. Feng, J. et al. Whole-Genome Structural Variations Study in a Severe Acne Family. J. Invest Dermatol 145, 2098–2102.e2095 (2025).

    Article  CAS  PubMed  Google Scholar 

  35. Heng, A. H. S., Say, Y. H., Sio, Y. Y., Ng, Y. T. & Chew, F. T. Gene variants associated with acne vulgaris presentation and severity: a systematic review and meta-analysis. BMC Med Genomics 14, 103 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Common, J. E. A., Barker, J. N. & van Steensel, M. A. M. What does acne genetics teach us about disease pathogenesis? Br. J. Dermatol 181, 665–676 (2019).

    Article  CAS  PubMed  Google Scholar 

  37. Petridis, C. et al. Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nat. Commun. 9, 5075 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Mitchell, B. L. et al. Genome-wide association meta-analysis identifies 29 new acne susceptibility loci. Nat. Commun. 13, 702 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Teder-Laving, M. et al. Genome-wide meta-analysis identifies novel loci conferring risk of acne vulgaris. Eur. J. Hum. Genet 32, 1136–1143 (2024).

    Article  CAS  PubMed  Google Scholar 

  40. Shang, W., Tan, A. Y. Q., van Steensel, M. A. M. & Lim, X. Aberrant Wnt Signaling Induces Comedo-Like Changes in the Murine Upper Hair Follicle. J. Invest Dermatol 142, 2603–2612.e2606 (2022).

    Article  CAS  PubMed  Google Scholar 

  41. Kim, B. R. et al. Causal association between polyunsaturated fatty acids and acne: a two-sample Mendelian randomization study. Br. J. Dermatol 192, 1106–1114 (2025).

    Article  CAS  PubMed  Google Scholar 

  42. Ullah, R. et al. Absence of GSTT1 and polymorphisms in GSTP1 and TP53 are associated with the incidence of acne vulgaris. Ski. Res Technol. 29, e13333 (2023).

    Article  Google Scholar 

  43. Chi, Y., Yang, X., Deng, D., Li, P. & Zhang, Y. Polymorphisms in MTNR1A (rs2119882) and CLOCK (rs1801260) genes are associated with facial acne susceptibility in gas station workers. PLoS One 20, e0329150 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Mohammed, S. M. A., Sabry, H. H., Ameen, S. G. & Salem, R. M. MMP-1 (519 A/G) and TIMP-1 (372 T/C) genes polymorphism in an Egyptian sample of Acne vulgaris patients. J. Cosmet. Dermatol 21, 1705–1711 (2022).

    Article  PubMed  Google Scholar 

  45. Wen, X., Du, H., Hao, X., Zhang, H. & Guo, Y. TIMP2 genetic variation rs4789932 may associate with an increased risk of developing acne scarring based on a case‒control study of Chinese Han population. J. Cosmet. Dermatol 21, 4740–4747 (2022).

    Article  PubMed  Google Scholar 

  46. Abdelaal, E. B. et al. Association of a novel Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-3928C/T and GM-CSF(3606T⁄C) Promoter gene polymorphisms with the pathogenesis and severity of acne vulgaris: A case‒controlled study. J. Cosmet. Dermatol 20, 3679–3683 (2021).

    Article  PubMed  Google Scholar 

  47. Gong, K., Ji, X., Wu, S., Zhao, D. D. & Zhu, M. DNA Methylation at cg18095732 Modulates ZDHHC20 Expression and Decreases Acne Vulgaris Risk. Clin. Cosmet. Investig. Dermatol 18, 2579–2590 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rahaman, S. M. A. et al. Association of insulin-like growth factor (IGF)-1 gene polymorphisms with plasma levels of IGF-1 and acne severity. J. Am. Acad. Dermatol 75, 768–773 (2016).

    Article  CAS  PubMed  Google Scholar 

  49. Dessinioti, C., Koukkou, E., Kontochristopoulos, G. & Antoniou, C. Are normal serum levels of insulin-like growth factor-1 clinically relevant in acne? J. Am. Acad. Dermatol 76, e223 (2017).

    Article  PubMed  Google Scholar 

  50. Fan, M. et al. Potential role of insulin-like growth factor 1 and growth hormone in acneiform eruptions: evidence from a rat model of acromegaly. J. Endocrinol. Invest. 49, 55–68 (2026).

  51. Nock, M. R., White, M. A. & Cohen, J. M. Acne and eating disorders: A retrospective cohort study of US adults. J. Eur. Acad. Dermatol. Venereol. 40, e1–e4 (2026).

  52. Aghasi, M. et al. Dairy intake and acne development: A meta-analysis of observational studies. Clin. Nutr. 38, 1067–1075 (2019).

    Article  PubMed  Google Scholar 

  53. Smith, R. N., Braue, A., Varigos, G. A. & Mann, N. J. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. J. Dermatol Sci. 50, 41–52 (2008).

    Article  CAS  PubMed  Google Scholar 

  54. Burris, J., Shikany, J. M., Rietkerk, W. & Woolf, K. A Low Glycemic Index and Glycemic Load Diet Decreases Insulin-like Growth Factor-1 among Adults with Moderate and Severe Acne: A Short-Duration, 2-Week Randomized Controlled Trial. J. Acad. Nutr. Diet. 118, 1874–1885 (2018).

    Article  PubMed  Google Scholar 

  55. Daszkiewicz, M., Rozanska, D. & Regulska-Ilow, B. The Relationship between Chocolate Consumption and the Severity of Acne Lesions-A Crossover Study. Foods 13, 1993 (2024).

  56. He, S. et al. Beverage consumption increases acne risk in Chinese adults: A cross-sectional study. J. Am. Acad. Dermatol 93, 792–795 (2025).

    Article  PubMed  Google Scholar 

  57. Darlenski, R., Mihaylova, V. & Handjieva-Darlenska, T. The Link Between Obesity and the Skin. Front Nutr. 9, 855573 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  58. Melnik, B. C. Lifetime Impact of Cow’s Milk on Overactivation of mTORC1: From Fetal to Childhood Overgrowth, Acne, Diabetes, Cancers, and Neurodegeneration. Biomolecules 11, 404 (2021).

  59. Lake, E. JAAD Game Changers: Consumption of dairy in teenagers with and without acne. J. Am. Acad. Dermatol 92, 800 (2025).

    Article  PubMed  Google Scholar 

  60. Clatici, V. G. et al. Diseases of Civilization - Cancer, Diabetes, Obesity and Acne - the Implication of Milk, IGF-1 and mTORC1. Maedica (Bucur.) 13, 273–281 (2018).

    PubMed  PubMed Central  Google Scholar 

  61. Say, Y. H. et al. Golgin A7 family member B (GOLGA7B) is a plausible novel gene associating high glycemic index diet with acne vulgaris. Exp. Dermatol 31, 1208–1219 (2022).

    CAS  PubMed  Google Scholar 

  62. Nakamizo, S. et al. High-fat diet induces a predisposition to follicular hyperkeratosis and neutrophilic folliculitis in mice. J. Allergy Clin. Immunol. 148, 473–485 e410 (2021).

    Article  CAS  PubMed  Google Scholar 

  63. Barrea, L. et al. The effect of the ketogenic diet on Acne: Could it be a therapeutic tool? Crit. Rev. Food Sci. Nutr. 64, 6850–6869 (2024).

    Article  CAS  PubMed  Google Scholar 

  64. Pardo, L. M. Linking levels of polyunsaturated fatty acids to acne risk. Br. J. Dermatol 192, 972–973 (2025).

    Article  PubMed  Google Scholar 

  65. Guertler, A. et al. Deficit of Omega-3 Fatty Acids in Acne Patients-A Cross-Sectional Pilot Study in a German Cohort. Life (Basel) 14, 519 (2024).

  66. Shields, A. et al. Safety and Effectiveness of Oral Nutraceuticals for Treating Acne: A Systematic Review. JAMA Dermatol 159, 1373–1382 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  67. Zujko-Kowalska, K., Jankowska, B. & Zujko, M. E. The Antioxidant Power of a Diet May Improve the Quality of Life of Young Women with Acne Vulgaris. Nutrients 16, 1270 (2024).

  68. Zhang, L. et al. Exploring clinical and genetic evidence in association between unsaturated fatty acids and acne. Eur. J. Nutr. 64, 130 (2025).

    Article  CAS  PubMed  Google Scholar 

  69. Guertler, A. et al. Clinical effects of omega-3 fatty acids on acne vulgaris. J. Dtsch Dermatol Ges. 20, 1023–1027 (2022).

    PubMed  Google Scholar 

  70. Fabbrocini, G. et al. Supplementation with Lactobacillus rhamnosus SP1 normalizes skin expression of genes implicated in insulin signaling and improves adult acne. Benef. Microbes 7, 625–630 (2016).

    Article  CAS  PubMed  Google Scholar 

  71. Salem, I., Ramser, A., Isham, N. & Ghannoum, M. A. The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. Front Microbiol 9, 1459 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  72. Penso, L. et al. Association Between Adult Acne and Dietary Behaviors: Findings From the NutriNet-Sante Prospective Cohort Study. JAMA Dermatol 156, 854–862 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wolkenstein, P. et al. Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. J. Eur. Acad. Dermatol Venereol. 32, 298–306 (2018).

    Article  CAS  PubMed  Google Scholar 

  74. Zhang, J. Z. et al. Association between acne and smoking: systematic review and meta-analysis of observational studies. Chin. Med J. (Engl.) 134, 1887–1888 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Crivellari, I. et al. SRB1 as a new redox target of cigarette smoke in human sebocytes. Free Radic. Biol. Med 102, 47–56 (2017).

    Article  CAS  PubMed  Google Scholar 

  76. Kong, E. Q. Z., Subramaniyan, V. & Lubau, N. S. A. Uncovering the impact of alcohol on internal organs and reproductive health: Exploring TLR4/NF-kB and CYP2E1/ROS/Nrf2 pathways. Anim. Model Exp. Med 7, 444–459 (2024).

    Article  CAS  Google Scholar 

  77. Ruiter-Lopez, L., Khan, M. A. S., Wang, X. & Song, B. J. Roles of Oxidative Stress and Autophagy in Alcohol-Mediated Brain Damage. Antioxidants (Basel) 14, 302 (2025).

  78. Kleemann, J. et al. Alcohol Promotes Lipogenesis in Sebocytes-Implications for Acne. Cells 13, 328 (2024).

  79. Guertler, A. et al. Dietary Patterns in Acne and Rosacea Patients-A Controlled Study and Comprehensive Analysis. Nutrients 15, 4405 (2023).

  80. Goldsmith, P., Gao, J., Rajpopat, S. & Goiriz, R. Mask related acne is a problem for healthcare workers and those with pigmented skins. BMJ 374, n1695 (2021).

    Article  PubMed  Google Scholar 

  81. Na, H. H. et al. Facemask acne attenuation through modulation of indirect microbiome interactions. NPJ Biofilms Microbiomes 10, 50 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Li, F. et al. BMAL1 regulates Propionibacterium acnes-induced skin inflammation via REV-ERBalpha in mice. Int J. Biol. Sci. 18, 2597–2608 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Di Landro, A. et al. Adult female acne and associated risk factors: Results of a multicenter case‒control study in Italy. J. Am. Acad. Dermatol 75, 1134–1141.e1131 (2016).

    Article  PubMed  Google Scholar 

  84. Alexopoulos, A. & Chrousos, G. P. Stress-related skin disorders. Rev. Endocr. Metab. Disord. 17, 295–304 (2016).

    Article  CAS  PubMed  Google Scholar 

  85. Agrawal, D. A. & Khunger, N. A Morphological Study of Acne Scarring and Its Relationship between Severity and Treatment of Active Acne. J. Cutan. Aesthet. Surg. 13, 210–216 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  86. Sevimli Dikicier, B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J. Int Med Res 47, 2987–2992 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Min, M. et al. Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Noncystic Acne. Dermatol Ther. (Heidelb.) 15, 1331–1350 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  88. Al-Ghanayem, A. A. In vitro anti-acne activity of Teucrium oliverianum methanolic extract against Cutibacterium acnes. Front Pharm. 15, 1388625 (2024).

    Article  CAS  Google Scholar 

  89. Han, X. D., Oon, H. H. & Goh, C. L. Epidemiology of postadolescence acne and adolescence acne in Singapore: a 10-year retrospective and comparative study. J. Eur. Acad. Dermatol Venereol. 30, 1790–1793 (2016).

    Article  CAS  PubMed  Google Scholar 

  90. Baroud, S., Wu, J. & Zouboulis, C. C. Acne Syndromes and Mosaicism. Biomedicines 9, 1735 (2021).

  91. Nakayama, E. et al. Optimal blue light irradiation conditions for the treatment of acne vulgaris in a mouse model. J. Photochem Photobio. B 239, 112651 (2023).

    Article  CAS  Google Scholar 

  92. Abad-Casintahan, F. et al. Frequency and characteristics of acne-related postinflammatory hyperpigmentation. J. Dermatol 43, 826–828 (2016).

    Article  PubMed  Google Scholar 

  93. Thiboutot, D., Zaenglein, A. & Layton, A. M. What Matters the Most to Adult Women With Acne? JAMA Dermatol 157, 1035–1037 (2021).

    Article  PubMed  Google Scholar 

  94. Miskinyte, S. et al. Clinical characteristics and genetic analysis of 14 patients affected with acne (A) fulminans and hidradenitis suppurativa (SH): ASH syndrome, a new phenotypic entity. J. Am. Acad. Dermatol 92, 332–334 (2025).

    Article  CAS  PubMed  Google Scholar 

  95. Madanchi, M., Jeker, F., Juratli, H. A. & Curatolo, R. Acne Conglobata and Bimekizumab. JAMA Dermatol 161, 666–668 (2025).

    Article  PubMed  Google Scholar 

  96. Yesudian, P. D. Treating cystic and conglobate acne with 13-cis-retinoic acid. Clin. Exp. Dermatol 45, 1109–1110 (2020).

    Article  CAS  PubMed  Google Scholar 

  97. Du, L. et al. Fire needle pretreatment with 5-aminolevulinic acid photodynamic therapy combined with low-dose isotretinoin in the treatment of severe refractory nodulocystic acne. Photodiagnosis Photodyn. Ther. 47, 104215 (2024).

    Article  CAS  PubMed  Google Scholar 

  98. Meister, H., Shihab, N., Lebwohl, M. & Silverberg, N. B. Large inflamed facial cysts in teenagers. Pediatr. Dermatol 37, 1055–1056 (2020).

    Article  PubMed  Google Scholar 

  99. Stratman, E. et al. Outcomes of the American Board of Dermatology focused Practice Improvement program 2016-2023. J. Am. Acad. Dermatol 92, 292–298 (2025).

    Article  PubMed  Google Scholar 

  100. Cline, A. et al. Multiethnic training in residency: a survey of dermatology residents. Cutis 105, 310–313 (2020).

    Article  PubMed  Google Scholar 

  101. Bernardis, E. et al. Development and Initial Validation of a Multidimensional Acne Global Grading System Integrating Primary Lesions and Secondary Changes. JAMA Dermatol 156, 296–302 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  102. Cho, S. I., Yang, J. H. & Suh, D. H. Analysis of trends and status of physician-based evaluation methods in acne vulgaris from 2000 to 2019. J. Dermatol 48, 42–48 (2021).

    Article  PubMed  Google Scholar 

  103. A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions. Br J Dermatol 186, e111-e133 (2022).

  104. Szabo, A., Brodszky, V. & Rencz, F. A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16. Br. J. Dermatol 186, 485–495 (2022).

    Article  CAS  PubMed  Google Scholar 

  105. Alatas, E. T., Kara Polat, A., Kalayci, M., Dogan, G. & Akin Belli, A. Plasma dermcidin levels in acne patients, and the effect of isotretinoin treatment on dermcidin levels. Dermatol Ther. 32, e13044 (2019).

    Article  PubMed  Google Scholar 

  106. Griffiths, D. et al. Validation of the Acne Core Outcomes Research Network Patient Global Assessment for Acne. JAMA Dermatol 161, 332–334 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  107. Yu, R., Fei, W., Ning, X. & Cui, Y. Interrater variability and consistency within four acne grading systems recommended in China, USA, and Europe. J. Cosmet. Dermatol 21, 6156–6162 (2022).

    Article  PubMed  Google Scholar 

  108. Barbieri, J. S. et al. Establishing minimally important difference thresholds for lesion counts in acne clinical studies. J. Am. Acad. Dermatol 92, 1117–1119 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  109. Fleshner, L., Roster, K., Balboul, S. & Lipner, S. R. Bridging the gap in acne vulgaris research for skin of color patients. J. Am. Acad. Dermatol 92, e137–e138 (2025).

    Article  PubMed  Google Scholar 

  110. Hopkins, Z. H., Thiboutot, D., Homsi, H. A., Perez-Chada, L. M. & Barbieri, J. S. Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Acne Vulgaris: A Systematic Review of Measure Development and Measurement Properties. JAMA Dermatol 158, 900–911 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  111. Shields, A. et al. Identifying Core Outcome Domains in Chronic Skin Disease Using the Best‒Worst Scaling Method. JAMA Dermatol 160, 441–446 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  112. Mascarenhas, P. P., Sannidhan, M. S., Pinto, A. J., Camero, D. & Martis, J. E. Improving acne severity detection: a GAN framework with contour accentuation for image deblurring. Front Bioinform 5, 1485797 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  113. Singer, H. M. et al. Using Network Oriented Research Assistant (NORA) Technology to Compare Digital Photographic With In-Person Assessment of Acne Vulgaris. JAMA Dermatol 154, 188–190 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  114. Tanizaki, H., Tanioka, M., Yamashita, Y. & Hayashi, N. Quantitative evaluation of atrophic acne scars using 3D image analysis with reflected LED light. Ski. Res Technol. 26, 20–24 (2020).

    Article  Google Scholar 

  115. Lee, J. S. et al. Robustness of automated acne lesion detection across various imaging conditions: A comparative analysis with dermatologists. J. Eur. Acad. Dermatol Venereol. 39, e439–e441 (2025).

    Article  PubMed  Google Scholar 

  116. Moon, J. et al. Atrophic acne scar: a process from altered metabolism of elastic fibers and collagen fibers based on transforming growth factor-beta1 signalling. Br. J. Dermatol 181, 1226–1237 (2019).

    Article  CAS  PubMed  Google Scholar 

  117. Carlavan, I. et al. Atrophic scar formation in patients with acne involves long-acting immune responses with plasma cells and alteration of sebaceous glands. Br. J. Dermatol 179, 906–917 (2018).

    Article  CAS  PubMed  Google Scholar 

  118. Berman, B., Maderal, A. & Raphael, B. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment. Dermatol Surg. 43, S3–S18 (2017).

    Article  CAS  PubMed  Google Scholar 

  119. Kim, E. Y., Wong, J. H., Hussain, A. & Khachemoune, A. Evidence-based management of cutaneous scarring in dermatology part 2: atrophic acne scarring. Arch. Dermatol Res 316, 19 (2023).

    Article  PubMed  Google Scholar 

  120. Lee, Y. J., Lee, C. Y. & Shin, M. K. A Neglected Acne Scar Type: Papular Acne Scars and Their Correlations With Keloid Scars. Dermatol Surg. 47, 1347–1351 (2021).

    Article  CAS  PubMed  Google Scholar 

  121. Shields, A. et al. Evaluation of Stigma Toward Individuals With Acne. JAMA Dermatol 160, 93–98 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  122. Tosun, N., Tosun, M., Digis, M. & Younis, M. Internalized Stigma in Acne Vulgaris Patients and Relationship with Quality of Life, Disease Severity. Healthcare (Basel) 13, 1359 (2025).

  123. Davern, J. & O’Donnell, A. T. Stigma predicts health-related quality of life impairment, psychological distress, and somatic symptoms in acne sufferers. PLoS One 13, e0205009 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  124. Kluger, N. et al. Impact of acne on women’s social media and dating apps photo activity. J. Eur. Acad. Dermatol Venereol. 39, e5–e7 (2025).

    Article  CAS  PubMed  Google Scholar 

  125. Taylor, M. T. & Barbieri, J. S. Depression screening at visits for acne in the United States, 2005-2016. J. Am. Acad. Dermatol 83, 936–938 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  126. Sood, S., Jafferany, M. & Vinaya Kumar, S. J. J. O. C. D. Depression, psychiatric comorbidities, and psychosocial implications associated with acne vulgaris. J Cosmet Dermatol 19, 3177–3182 (2020).

  127. Samuels, D. V., Rosenthal, R., Lin, R., Chaudhari, S. & Natsuaki, M. N. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J. Am. Acad. Dermatol 83, 532–541 (2020).

    Article  PubMed  Google Scholar 

  128. Vallerand, I. et al. Risk of depression among patients with acne in the UK: a population-based cohort study. Br. J. Dermatol. 178, e194–e195 (2018).

  129. Barlow, R. et al. Suicide and suicidality in children and adolescents with chronic skin disorders: a systematic review. Acta Derm. Venereol 103, 1502 (2023).

  130. Hughes, O. & Bewley, A. Is it truly ever ‘just acne’? Considering the psychodermatology of acne. Br. J. Dermatol 189, i11–i16 (2023).

    Article  PubMed  Google Scholar 

  131. Modanlo, N. & Jafferany, M. Navigating the ethics of working with patients who refuse a psychiatry referral. J. Am. Acad. Dermatol. 94, e7-e8 (2025).

  132. Evaluation, I.f.H.M.a. Acne vulgaris - Methods Appendices 2021. (2021).

  133. Paller, A. S. et al. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders. JAMA Dermatol 160, 621–630 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  134. Azziz, R. et al. Polycystic ovary syndrome. Nat. Rev. Dis. Prim. 2, 16057 (2016).

    Article  PubMed  Google Scholar 

  135. Nagpal, M., De, D., Handa, S., Pal, A. & Sachdeva, N. Insulin Resistance and Metabolic Syndrome in Young Men With Acne. JAMA Dermatol 152, 399–404 (2016).

    Article  PubMed  Google Scholar 

  136. Sinikumpu, S. P., Jokelainen, J., Tasanen, K. & Huilaja, L. Cardiovascular and Metabolic Profile of Subjects with Acne in a Cohort of Middle-aged Patients: A General Population Study of 1,932 Subjects. Acta Derm. Venereol. 103, adv5921 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  137. Wertenteil, S., Strunk, A. & Garg, A. Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. J. Am. Acad. Dermatol 80, 1308–1313 (2019).

    Article  PubMed  Google Scholar 

  138. Wright, S., Strunk, A. & Garg, A. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin. J. Am. Acad. Dermatol 84, 41–45 (2021).

    Article  CAS  PubMed  Google Scholar 

  139. Honap, S. et al. Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clin. Gastroenterol. Hepatol. 24, 484–492.e7 (2026).

  140. Martinez, J. et al. Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis. JAMA Dermatol 159, 1339–1345 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  141. Hu, H. H. & Li, J. H. Acne Fulminans. N. Engl. J. Med 391, 1440 (2024).

    Article  PubMed  Google Scholar 

  142. Chien, A. L. et al. Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics. JAMA Dermatol 155, 425–434 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  143. Karimkhani, C. et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol 153, 406–412 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  144. Moradi Tuchayi, S. et al. Acne vulgaris. Nat. Rev. Dis. Prim. 1, 15029 (2015).

    Article  PubMed  Google Scholar 

  145. Duz, T. et al. High-Resolution Spatial Map of the Human Facial Sebaceous Gland Reveals Marker Genes and Decodes Sebocyte Differentiation. J. Invest. Dermatol. 146, 40–54.e14 (2026).

  146. Schmidt, M. et al. A spatial portrait of the human sebaceous gland transcriptional program. J. Biol. Chem. 300, 107442 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Deng, M. et al. Analysis of intracellular communication reveals consistent gene changes associated with early-stage acne skin. Cell Commun. Signal 22, 400 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Starr, N. J. et al. Elucidating the molecular landscape of the stratum corneum. Proc. Natl. Acad. Sci. USA 119, e2114380119 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Josse, G. et al. High bacterial colonization and lipase activity in microcomedones. Exp. Dermatol 29, 168–176 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Saurat, J. H. Strategic Targets in Acne: The Comedone Switch in Question. Dermatology 231, 105–111 (2015).

    Article  PubMed  Google Scholar 

  151. Okoro, O. E. et al. Lipidomics of facial sebum in the comparison between acne and nonacne adolescents with dark skin. Sci. Rep. 11, 16591 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Choi, K., Jin, M., Zouboulis, C. C. & Lee, Y. Increased Lipid Accumulation under Hypoxia in SZ95 Human Sebocytes. Dermatology 237, 131–141 (2021).

    Article  CAS  PubMed  Google Scholar 

  153. Clayton, R. W. et al. Homeostasis of the sebaceous gland and mechanisms of acne pathogenesis. Br. J. Dermatol 181, 677–690 (2019).

    Article  CAS  PubMed  Google Scholar 

  154. Liu, Y. et al. Ludwigia adscendens (L.) Hara extract inhibits sebum overproduction and improves sebaceous gland function via the PPARgamma/LXRalpha/SREBP1 pathway. J. Ethnopharmacol. 353, 120416 (2025).

    Article  CAS  PubMed  Google Scholar 

  155. Cai, C. et al. Paeoniflorin mitigates insulin-like growth factor 1-induced lipogenesis and inflammation in human sebocytes by inhibiting the PI3K/Akt/FoxO1 and JAK2/STAT3 signaling pathways. Nat. Prod. Bioprospect 14, 56 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Esler, W. P. et al. Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition. Sci. Transl. Med. 11, eaau8465 (2019).

  157. Okoro, O. E., Camera, E., Flori, E. & Ottaviani, M. Insulin and the sebaceous gland function. Front Physiol. 14, 1252972 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  158. Yang, T. et al. The role of NPY2R/NFATc1/DYRK1A regulatory axis in sebaceous glands for sebum synthesis. Cell Mol. Biol. Lett. 28, 60 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Jaitin, D. A. et al. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. Cell 178, 686–698.e614 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Clayton, R. W. et al. Neuroendocrinology and neurobiology of sebaceous glands. Biol. Rev. Camb. Philos. Soc. 95, 592–624 (2020).

    Article  PubMed  Google Scholar 

  161. Su, Z. et al. Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist. J. Nanobiotechnology 21, 55 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Zhu, J. et al. Biomimetic hyaluronic acid-stabilized zinc oxide nanoparticles in acne treatment: A preclinical and clinical approach. J. Control Release 382, 113754 (2025).

    Article  CAS  PubMed  Google Scholar 

  163. Oules, B. et al. Mutant Lef1 controls Gata6 in sebaceous gland development and cancer. EMBO J. 38, e100526 (2019).

  164. Swanson, J. B., Vagnozzi, A. N., Veniaminova, N. A. & Wong, S. Y. Loss of Gata6 causes dilation of the hair follicle canal and sebaceous duct. Exp. Dermatol 28, 345–349 (2019).

    Article  CAS  PubMed  Google Scholar 

  165. Kurokawa, I. & Nakase, K. Recent advances in understanding and managing acne. F1000Res 9, F1000 (2020).

  166. Hazarika, N. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. J. Dermatol. Treat. 32, 277–285 (2021).

    Article  CAS  Google Scholar 

  167. Kim, E. O. et al. The Secretion of Inflammatory Cytokines Triggered by TLR2 Through Calcium-Dependent and Calcium-Independent Pathways in Keratinocytes. Mediators Inflamm. 2024, 8892514 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Cong, T. X. et al. From pathogenesis of acne vulgaris to anti-acne agents. Arch. Dermatol Res 311, 337–349 (2019).

    Article  CAS  PubMed  Google Scholar 

  169. Eliasse, Y. et al. IL-17(+) Mast Cell/T Helper Cell Axis in the Early Stages of Acne. Front Immunol. 12, 740540 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Nguyen, C. T., Sah, S. K., Zouboulis, C. C. & Kim, T. Y. Inhibitory effects of superoxide dismutase 3 on Propionibacterium acnes-induced skin inflammation. Sci. Rep. 8, 4024 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  171. Hou, X. X. et al. Aryl Hydrocarbon Receptor Modulates the Expression of TNF-alpha and IL-8 in Human Sebocytes via the MyD88-p65NF-kappaB/p38MAPK Signaling Pathways. J. Innate Immun. 11, 41–51 (2019).

    Article  CAS  PubMed  Google Scholar 

  172. Shi, Y., Zhang, X., Pei, S. & Wang, Y. Ethnopharmacological study on Adenosma buchneroides Bonati inhibiting inflammation via the regulation of TLR4/MyD88/NF-kappaB signaling pathway. Nat. Prod. Bioprospect 14, 36 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Werner, J. L. et al. Induction of Pulmonary Granuloma Formation by Propionibacterium acnes Is Regulated by MyD88 and Nox2. Am. J. Respir. Cell Mol. Biol. 56, 121–130 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Wei, Z. et al. TRPV3 promotes sebocyte inflammation via transcriptional modulating TLR2 in acne. Biochim Biophys. Acta Mol. Basis Dis. 1870, 167195 (2024).

    Article  CAS  PubMed  Google Scholar 

  175. Liang, J. et al. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci. Rep. 14, 3065 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Xu, D. et al. Reduction of peripheral natural killer cells in patients with SAPHO syndrome. Clin. Exp. Rheumatol. 37, 12–18 (2019).

    PubMed  Google Scholar 

  177. Mistry, P. et al. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann. Rheum. Dis. 77, 1825–1833 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. He, Y., Hara, H. & Nunez, G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 41, 1012–1021 (2016).

    Article  CAS  PubMed  Google Scholar 

  179. Yang, G. et al. Licochalcone A attenuates acne symptoms mediated by suppression of NLRP3 inflammasome. Phytother. Res 32, 2551–2559 (2018).

    Article  CAS  PubMed  Google Scholar 

  180. Erdei, L. et al. TNIP1 Regulates Cutibacterium acnes-Induced Innate Immune Functions in Epidermal Keratinocytes. Front Immunol. 9, 2155 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  181. Sawada, Y. et al. Cutaneous innate immune tolerance is mediated by epigenetic control of MAP2K3 by HDAC8/9. Sci. Immunol. 6, eabe1935 (2021).

  182. Sanford, J. A. et al. Inhibition of HDAC8 and HDAC9 by microbial short-chain fatty acids breaks immune tolerance of the epidermis to TLR ligands. Sci. Immunol. 1, eaah4609 (2016).

  183. Hughes, T. K. et al. Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies. Immunity 53, 878–894.e877 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. O’Neill, A. M. et al. Antimicrobial production by perifollicular dermal preadipocytes is essential to the pathophysiology of acne. Sci. Transl. Med 14, eabh1478 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  185. Mattii, M. et al. Sebocytes contribute to skin inflammation by promoting the differentiation of T helper 17 cells. Br. J. Dermatol 178, 722–730 (2018).

    Article  CAS  PubMed  Google Scholar 

  186. Mills, K. H. G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23, 38–54 (2023).

    Article  CAS  PubMed  Google Scholar 

  187. Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Baeten, D. et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N. Engl. J. Med. 373, 2534–2548 (2015).

    Article  CAS  PubMed  Google Scholar 

  189. Krainer, J., Siebenhandl, S. & Weinhausel, A. Systemic autoinflammatory diseases. J. Autoimmun. 109, 102421 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Zhang, J. & Shen, M. The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives. Clin. Rev. Allergy Immunol. 68, 27 (2025).

    Article  CAS  PubMed  Google Scholar 

  191. Deng, J., Yu, X. Q. & Wang, P. H. Inflammasome activation and Th17 responses. Mol. Immunol. 107, 142–164 (2019).

    Article  CAS  PubMed  Google Scholar 

  192. Varela Martins, T. et al. The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity. JCI Insight 9, e171894 (2024).

  193. Zwicker, S. et al. Th17 micromilieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation. PLoS One 12, e0175153 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  194. Thiboutot, D. M. & Nelson, A. M. Keeping the peace: commensal Cutibacterium acnes trains CD4+ TH17 cells to trap and kill. J. Clin. Invest. 131, e145379 (2021).

  195. Agak, G. W. et al. Extracellular traps released by antimicrobial TH17 cells contribute to host defense. J. Clin. Invest. 131, e141594 (2021).

  196. Balin, S. J. et al. Human antimicrobial cytotoxic T lymphocytes, defined by NK receptors and antimicrobial proteins, kill intracellular bacteria. Sci. Immunol. 3, eaat7668 (2018).

  197. Dеmina, O. M., Kartelishev, A. V., Karpova, E. I. & Danischuk, O. I. J. I. J. O. B. Role of Cytokines in the Pathogenesis of Acne. 7, 37–40 (2017).

  198. Yang, L., Shou, Y. H., Yang, Y. S. & Xu, J. H. Elucidating the immune infiltration in acne and its comparison with rosacea by integrated bioinformatics analysis. PLoS One 16, e0248650 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Sardana, K. & Verma, G. Propionibacterium acnes and the Th1/Th17 Axis, Implications in Acne Pathogenesis and Treatment. Indian J. Dermatol 62, 392–394 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  200. Farag, A. G. A. et al. Tissue expression of IL-17A and FOXP3 in acne vulgaris patients. J. Cosmet. Dermatol 20, 330–337 (2021).

    Article  PubMed  Google Scholar 

  201. Ali, N. et al. Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation. Cell 169, 1119–1129.e1111 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Jung, M. K., Kwak, J. E. & Shin, E. C. IL-17A-Producing Foxp3(+) Regulatory T Cells and Human Diseases. Immune Netw. 17, 276–286 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  203. Choi, J. H. et al. Essential requirement for nicastrin in marginal zone and B-1 B-cell development. Proc. Natl. Acad. Sci. USA 117, 4894–4901 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Ralser, D. J. et al. Mutations in gamma-secretase subunit-encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. J. Clin. Invest 127, 1485–1490 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  205. Thrane, K. et al. Single-Cell and Spatial Transcriptomic Analysis of Human Skin Delineates Intercellular Communication and Pathogenic Cells. J. Invest Dermatol 143, 2177–2192.e2113 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  206. Xu, Z. et al. Anatomically distinct fibroblast subsets determine skin autoimmune patterns. Nature 601, 118–124 (2022).

    Article  CAS  PubMed  Google Scholar 

  207. Blakney, A. K. et al. The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. ACS Nano 13, 5920–5930 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Cheng, J. B. et al. Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution. Cell Rep. 25, 871–883 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Yu, H. et al. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci. Rep. 14, 1521 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Hoffmann, M. H. & Griffiths, H. R. The dual role of Reactive Oxygen Species in autoimmune and inflammatory diseases: evidence from preclinical models. Free Radic. Biol. Med. 125, 62–71 (2018).

    Article  CAS  PubMed  Google Scholar 

  211. Glennon-Alty, L., Hackett, A. P., Chapman, E. A. & Wright, H. L. Neutrophils and redox stress in the pathogenesis of autoimmune disease. Free Radic. Biol. Med. 125, 25–35 (2018).

    Article  CAS  PubMed  Google Scholar 

  212. Chacko, B. K. et al. Pleiotropic effects of 4-hydroxynonenal on oxidative burst and phagocytosis in neutrophils. Redox Biol. 9, 57–66 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  213. Byrd, A. S. et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci. Transl. Med. 11, eaav5908 (2019).

  214. Jiang, M. et al. Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis. FASEB J. 33, 13241–13253 (2019).

    Article  CAS  PubMed  Google Scholar 

  215. Hirayama, D., Iida, T. & Nakase, H. The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. Int. J. Mol. Sci. 19, 92 (2017).

  216. Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832–844 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Hong, Y. K. et al. Profibrotic Subsets of SPP1(+) Macrophages and POSTN(+) Fibroblasts Contribute to Fibrotic Scarring in Acne Keloidalis. J. Invest Dermatol 144, 1491–1504.e1410 (2024).

    Article  CAS  PubMed  Google Scholar 

  218. Liu, P. et al. ALA-PDT augments intense inflammation in the treatment of acne vulgaris by COX2/TREM1 mediated M1 macrophage polarization. Biochem Pharm. 208, 115403 (2023).

    Article  CAS  PubMed  Google Scholar 

  219. Chen, S. et al. T-cell immunoglobulin and mucin domain-containing protein 3-mediated immunomodulation in myeloid cells and keratinocytes in the development of severe acne. Mol. Biomed. 6, 125 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  220. Sim, J. K., Heo, Y. J., Shin, J. H., Kim, S. S. & Seo, S. R. Gedunin Mitigates Cutibacterium acnes-Induced Skin Inflammation by Inhibiting the NF-kappaB Pathway. Pharmaceuticals (Basel) 18, 71 (2025).

  221. Cha, S. J., Kim, S. S., Shin, J. H. & Seo, S. R. Peiminine Exerts Its Anti-Acne Effects by Regulating the NF-kappaB Pathway. Antioxidants (Basel) 13, 131 (2024).

  222. Yang, S. X., Xiao, W. L. & Zhang, X. J. Essential oil of Saposhnikovia divaricata mitigates Cutibacterium acnes-induced inflammatory acne via Nrf2 pathway activation and NF-kappaB pathway inhibition. J. Ethnopharmacol. 355, 120647 (2026).

    Article  CAS  PubMed  Google Scholar 

  223. Huang, Y. et al. The combination of RL-QN15 and OH-CATH30 promotes the repair of acne via the TLR2/NF-kappaB pathway. Eur. J. Pharm. 989, 177233 (2025).

    Article  CAS  Google Scholar 

  224. Fischer, K. et al. Cutibacterium acnes Infection Induces Type I Interferon Synthesis Through the cGAS-STING Pathway. Front Immunol. 11, 571334 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Lesbats, J. et al. Macrophages recycle phagocytosed bacteria to fuel immunometabolic responses. Nature 640, 524–533 (2025).

    Article  CAS  PubMed  Google Scholar 

  226. Riviello, A. & Brenner, D. Bacteria-derived nutrient recycling: How phagocytosed bacteria regulate macrophage metabolism. Cell Metab. 37, 1046–1048 (2025).

    Article  CAS  PubMed  Google Scholar 

  227. Basu, S. & Rossol, M. You are what you eat: metabolic recycling of phagocytosed bacteria modulates macrophage immunity. Signal Transduct. Target Ther. 10, 133 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  228. Szulc-Dabrowska, L., Bossowska-Nowicka, M., Struzik, J. & Toka, F. N. Cathepsins in Bacteria-Macrophage Interaction: Defenders or Victims of Circumstance? Front Cell Infect. Microbiol 10, 601072 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Abd-Elrahman, I. et al. Characterizing Cathepsin Activity and Macrophage Subtypes in Excised Human Carotid Plaques. Stroke 47, 1101–1108 (2016).

    Article  CAS  PubMed  Google Scholar 

  230. Alam, S. et al. Upregulated cathepsin C induces macrophage M1 polarization through FAK-triggered p38 MAPK/NF-kappaB pathway. Exp. Cell Res 382, 111472 (2019).

    Article  CAS  PubMed  Google Scholar 

  231. Li, R. et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 26, 2447–2463 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  232. Pires, D. et al. Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages. Sci. Rep. 6, 32247 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  233. Zhang, N. et al. Cathepsin L promotes secretory IgA response by participating in antigen presentation pathways during Mycoplasma Hyopneumoniae infection. PLoS One 14, e0215408 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  234. Yadati, T., Houben, T., Bitorina, A. & Shiri-Sverdlov, R. The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells 9, 1679 (2020).

  235. Min, T. T. et al. Anti-CAMP1 IgG promotes macrophage phagocytosis of Cutibacterium acnes type II. Microbiol Res 285, 127749 (2024).

    Article  CAS  PubMed  Google Scholar 

  236. See, P. et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science 356, eaag3009 (2017).

  237. Del Fresno, C. & Sancho, D. cDC1s: New Orchestrators of Tissue Innate Immunity. Trends Immunol. 40, 559–561 (2019).

    Article  PubMed  Google Scholar 

  238. Dress, R. J., Wong, A. Y. & Ginhoux, F. Homeostatic control of dendritic cell numbers and differentiation. Immunol. Cell Biol. 96, 463–476 (2018).

    Article  PubMed  Google Scholar 

  239. Stagg, A. J. Intestinal Dendritic Cells in Health and Gut Inflammation. Front Immunol. 9, 2883 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  240. Del Vecchio, G. et al. Functional Dynamics of Dendritic Cells in Response to Cutibacteriumacnes Strains Associated with Healthy and Acne-Prone Skin. J. Invest Dermatol 145, 2363–2367 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  241. Del Fresno, C. et al. DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment. Science 362, 351–356 (2018).

    Article  PubMed  Google Scholar 

  242. Janela, B. et al. A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFalpha-Mediated Recruitment of Neutrophils. Immunity 50, 1069–1083.e1068 (2019).

    Article  CAS  PubMed  Google Scholar 

  243. Salvi, V. et al. Dendritic cell-derived VEGF-A plays a role in inflammatory angiogenesis of human secondary lymphoid organs and is driven by the coordinated activation of multiple transcription factors. Oncotarget 7, 39256–39269 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  244. Sun, C. et al. Integrated analysis of facial microbiome and skin physio-optical properties unveils cutotype-dependent aging effects. Microbiome 12, 163 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  245. Sripath, K., Bangperng, J., Chumnanpeun, P. & E-Kobon, T. Unique genetic diversity of Propionibacterium acnes isolated from human facial skins in Thailand revealed by the multilocus sequence typing scheme. BMC Microbiol 25, 643 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  246. Jusuf, N. K., Putra, I. B. & Sari, L. Differences of Microbiomes Found in Non-Inflammatory and Inflammatory Lesions of Acne Vulgaris. Clin. Cosmet. Investig. Dermatol 13, 773–780 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  247. Flowers, L. & Grice, E. A. The Skin Microbiota: Balancing Risk and Reward. Cell Host Microbe 28, 190–200 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  248. Cavallo, I. et al. Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents. Sci. Rep. 12, 21104 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  249. Grice, E. A. et al. Topographical and temporal diversity of the human skin microbiome. Science 324, 1190–1192 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  250. Naik, B., Sasikumar, J., B, V. & Das, S. P. Fungal coexistence in the skin mycobiome: a study involving Malassezia, Candida, and Rhodotorula. AMB Express 14, 26 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  251. Dreno, B. et al. Acne microbiome: From phyla to phylotypes. J. Eur. Acad. Dermatol Venereol. 38, 657–664 (2024).

    Article  CAS  PubMed  Google Scholar 

  252. Kim, J., Park, T., Kim, H. J., An, S. & Sul, W. J. Inferences in microbial structural signatures of acne microbiome and mycobiome. J. Microbiol 59, 369–375 (2021).

    Article  CAS  PubMed  Google Scholar 

  253. Wang, P. et al. Microecology in vitro model replicates the human skin microbiome interactions. Nat. Commun. 16, 3085 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  254. Sivamani, R. K., Maloh, J. & Nong, Y. Correlating the Gut Microbiota and Circulating Hormones with Acne Lesion Counts and Skin Biophysical Features. Microorganisms 11, 2049 (2023).

  255. McLaughlin, J. et al. Propionibacterium acnes and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. Microorganisms 7, 128 (2019).

  256. Almoughrabie, S. et al. Commensal Cutibacterium acnes induce epidermal lipid synthesis important for skin barrier function. Sci. Adv. 9, eadg6262 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  257. Ahle, C. M., Feidenhansl, C. & Bruggemann, H. Cutibacterium acnes. Trends Microbiol 31, 419–420 (2023).

    Article  CAS  PubMed  Google Scholar 

  258. Kaplan, J. B. et al. Poly-beta-(1->6)-N-acetyl-D-glucosamine mediates surface attachment, biofilm formation, and biocide resistance in Cutibacterium acnes. Front Microbiol 15, 1386017 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  259. Yu, Y. et al. Different Propionibacterium acnes Phylotypes Induce Distinct Immune Responses and Express Unique Surface and Secreted Proteomes. J. Invest Dermatol 136, 2221–2228 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  260. Oh, J. et al. Temporal Stability of the Human Skin Microbiome. Cell 165, 854–866 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  261. McLaughlin, J., Nagy, I., Miliotis, G. & McDowell, A. CUTIS-SEQ, a flexible bilocus sequence typing scheme that provides high resolution of Cutibacterium acnes strains across all subspecies. Anaerobe 79, 102671 (2023).

    Article  CAS  PubMed  Google Scholar 

  262. Qin, M. et al. Immune Activation and Glycolytic Responses to Cutibacterium acnes Cell Wall Polysaccharides. J. Invest. Dermatol. 145, 3126–3137.e8 (2025).

  263. Hamann, T. et al. Distinct Intraspecies Variation of Cutibacterium acnes and Staphylococcus epidermidis in Acne Vulgaris and Healthy Skin. Microorganisms 13, 299 (2025).

  264. Flowers, L., Campbell, A. & Uberoi, A. Cutibacterium acnes evolution: One pore at a time. Cell Host Microbe 30, 144–146 (2022).

    Article  CAS  PubMed  Google Scholar 

  265. Conwill, A. et al. Anatomy promotes neutral coexistence of strains in the human skin microbiome. Cell Host Microbe 30, 171–182.e177 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  266. Tett, A. et al. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes 3, 14 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  267. Zhou, W. et al. Host-Specific Evolutionary and Transmission Dynamics Shape the Functional Diversification of Staphylococcus epidermidis in Human Skin. Cell 180, 454–470.e418 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  268. O’Neill, A. M. et al. Genetic and Functional Analyses of Cutibacterium Acnes Isolates Reveal the Association of a Linear Plasmid with Skin Inflammation. J. Invest Dermatol 144, 116–124.e114 (2024).

    Article  PubMed  Google Scholar 

  269. Agak, G. W. et al. Phenotype and Antimicrobial Activity of Th17 Cells Induced by Propionibacterium acnes Strains Associated with Healthy and Acne Skin. J. Invest Dermatol 138, 316–324 (2018).

    Article  CAS  PubMed  Google Scholar 

  270. Christensen, G. J. et al. Antagonism between Staphylococcus epidermidis and Propionibacterium acnes and its genomic basis. BMC Genomics 17, 152 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  271. Megyeri, K. et al. Propionibacterium acnes Induces Autophagy in Keratinocytes: Involvement of Multiple Mechanisms. J. Invest Dermatol 138, 750–759 (2018).

    Article  CAS  PubMed  Google Scholar 

  272. Kao, H. J. et al. Propionic acid produced by Cutibacterium acnes fermentation ameliorates ultraviolet B-induced melanin synthesis. Sci. Rep. 11, 11980 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  273. Sanford, J. A., O’Neill, A. M., Zouboulis, C. C. & Gallo, R. L. Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes. J. Immunol. 202, 1767–1776 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  274. Kim, H. J., Lee, B. J. & Kwon, A. R. The grease trap: uncovering the mechanism of the hydrophobic lid in Cutibacterium acnes lipase. J. Lipid Res 61, 722–733 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  275. Hajam, I. A. et al. Functional divergence of a bacterial enzyme promotes healthy or acneic skin. Nat. Commun. 14, 8061 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  276. Wang, Y. et al. The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines. J. Invest Dermatol 138, 2355–2364 (2018).

    Article  CAS  PubMed  Google Scholar 

  277. Huang, X. W. et al. Biological Evaluation of the Antibacterial Retinoid CD437 in Cutibacterium acnes Infection. Antimicrob. Agents Chemother. 67, e0167922 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  278. Mayslich, C. et al. Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation. Int J Mol Sci 23 (2022).

  279. Kwon, H. H. & Suh, D. H. Recent progress in the research about Propionibacterium acnes strain diversity and acne: pathogen or bystander? Int J. Dermatol 55, 1196–1204 (2016).

    Article  CAS  PubMed  Google Scholar 

  280. Spittaels, K. J. et al. Porphyrins produced by acneic Cutibacterium acnes strains activate the inflammasome by inducing K(+) leakage. iScience 24, 102575 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  281. Shafiuddin, M. et al. Cutibacterium Adaptation to Life on Humans Provides a Potential C acnes Infection Biomarker. J. Invest. Dermatol. 146, 198–213 (2025).

  282. Keshari, S. et al. Prospects of acne vaccines targeting secreted virulence factors of Cutibacterium acnes. Expert Rev. Vaccines 18, 433–437 (2019).

    Article  CAS  PubMed  Google Scholar 

  283. Lomakin, I. B., Devarkar, S. C., Patel, S., Grada, A. & Bunick, C. G. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Res 51, 2915–2930 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  284. Harper, J. C. et al. Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies. J. Am. Acad. Dermatol 89, 832–834 (2023).

    Article  CAS  PubMed  Google Scholar 

  285. Knodlseder, N. et al. Delivery of a sebum modulator by an engineered skin microbe in mice. Nat. Biotechnol. 42, 1661–1666 (2024).

    Article  CAS  PubMed  Google Scholar 

  286. Wu, Y., Chen, Y., Chen, B., Wu, W. & Yang, J. DNA methylation mediated genetic risk in severe acne in a young men population. Front Med (Lausanne) 10, 1196149 (2023).

  287. Liu, L. et al. DNA methylation profiling and integrative multiomics analysis of skin samples reveal important contribution of epigenetics and immune response in the pathogenesis of acne vulgaris. Clin. Immunol. 255, 109773 (2023).

    Article  CAS  PubMed  Google Scholar 

  288. Abdelkader, H. A., Amin, I., Rashed, L. A., Samir, M. & Ezzat, M. Histone deacetylase 1 in patients with alopecia areata and acne vulgaris: An epigenetic alteration. Australas. J. Dermatol 63, e138–e141 (2022).

    Article  PubMed  Google Scholar 

  289. Shin, H. S., Zouboulis, C. C., Kim, M. K., Lee, D. H. & Chung, J. H. Minocycline suppresses lipogenesis via inhibition of p300 histone acetyltransferase activity in human SZ95 sebocytes. J. Eur. Acad. Dermatol Venereol. 36, 1325–1333 (2022).

    Article  CAS  PubMed  Google Scholar 

  290. Shin, H. S. et al. Histone Deacetylase 1 Reduces Lipogenesis by Suppressing SREBP1 Transcription in Human Sebocyte Cell Line SZ95. Int. J. Mol. Sci. 22, 4477 (2021).

  291. Wang, H. et al. Identification of differentially methylated genes for severe acne by genome-wide DNA methylation and gene expression analysis. Epigenetics 18, 2199373 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  292. Van Steensel, M. A. M. The Genetics of Acne. Ann. Hum. Genet 89, 333–341 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  293. Pacella, G. N. et al. UTX (KDM6A) promotes differentiation noncatalytically in somatic self-renewing epithelia. Proc. Natl. Acad. Sci. USA 122, e2422971122 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  294. Zhang, S. et al. Serum exosomal microRNA profiling reveals a downregulation of hsa-miR-124-3p in patients with severe acne. Front Immunol. 16, 1554811 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  295. He, Y. et al. Nicastrin/miR-30a-3p/RAB31 Axis Regulates Keratinocyte Differentiation by Impairing EGFR Signaling in Familial Acne Inversa. J. Invest Dermatol 139, 124–134 (2019).

    Article  CAS  PubMed  Google Scholar 

  296. Zeng, R. et al. miR-146a Inhibits Biofilm-Derived Cutibacterium acnes-Induced Inflammatory Reactions in Human Keratinocytes. J. Invest Dermatol 139, 2488–2496.e2484 (2019).

    Article  CAS  PubMed  Google Scholar 

  297. Yang, S. et al. Knockdown of H19 Inhibits the Pathogenesis of Acne Vulgaris by Targeting the miR-196a/TLR2/NF-kappaB Axis. Inflammation 43, 1936–1947 (2020).

    Article  CAS  PubMed  Google Scholar 

  298. Vellaichamy, G. et al. An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics. Br. J. Dermatol 186, 508–519 (2022).

    Article  CAS  PubMed  Google Scholar 

  299. Liang, J. et al. Circular RNA expression profile analysis of severe acne by RNA-Seq and bioinformatics. J. Eur. Acad. Dermatol. Venereol. 32, 1986–1992 (2018).

    Article  CAS  PubMed  Google Scholar 

  300. Knodlseder, N. et al. Engineering selectivity of Cutibacterium acnes phages by epigenetic imprinting. PLoS Pathog. 18, e1010420 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  301. Pondeljak, N. & Lugovic-Mihic, L. Stress-induced Interaction of Skin Immune Cells, Hormones, and Neurotransmitters. Clin. Ther. 42, 757–770 (2020).

    Article  CAS  PubMed  Google Scholar 

  302. Zhang, H. et al. Role of stress in skin diseases: A neuroendocrine-immune interaction view. Brain Behav. Immun. 116, 286–302 (2024).

    Article  CAS  PubMed  Google Scholar 

  303. Xu, Y., Guan, X., Zhou, R. & Gong, R. Melanocortin 5 receptor signaling pathway in health and disease. Cell Mol. Life Sci. 77, 3831–3840 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  304. Slominski, R. M., Raman, C., Jetten, A. M. & Slominski, A. T. Neuro-immuno-endocrinology of the skin: how environment regulates body homeostasis. Nat. Rev. Endocrinol. 21, 495–509 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  305. Feng, X., Zhan, H. & Sokol, C. L. Sensory neuronal control of skin barrier immunity. Trends Immunol. 45, 371–380 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  306. Flayer, C. H. et al. A gammadelta T-cell-IL-3 axis controls allergic responses through sensory neurons. Nature 634, 440–446 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  307. Kim, H., Jang, J. H., Kim, H. R. & Cho, J. H. Novel-designed antimicrobial peptides with dual antimicrobial and anti-inflammatory actions against Cutibacterium acnes for acne vulgaris therapy. Biochem Pharm. 232, 116708 (2025).

    Article  CAS  PubMed  Google Scholar 

  308. Zhao, T. et al. Temporin-GHa derived peptide shows inhibitory efficacy against Cutibacterium acnes and alleviates inflammatory reactions in acne vulgaris. Int Immunopharmacol. 157, 114756 (2025).

    Article  CAS  PubMed  Google Scholar 

  309. Lim, H. W. et al. The burden of skin disease in the United States. J. Am. Acad. Dermatol 76, 958–972.e952 (2017).

    Article  PubMed  Google Scholar 

  310. Bell, M. A., Whang, K. A., Thomas, J., Aguh, C. & Kwatra, S. G. Racial and Ethnic Disparities in Access to Emerging and Frontline Therapies in Common Dermatological Conditions: A Cross-Sectional Study. J. Natl. Med Assoc. 112, 650–653 (2020).

    PubMed  Google Scholar 

  311. Xu, J., Mavranezouli, I., Kuznetsov, L., Murphy, M. S. & Healy, E. J. B. Management of acne vulgaris: summary of NICE guidance. BMJ 374, n1800 (2021).

  312. Dessinioti, C. Advances in acne clinical research: a new class of topical treatment for moderate-to-severe facial acne. Br. J. Dermatol 187, 455–456 (2022).

    Article  PubMed  Google Scholar 

  313. Xu, B. et al. Optimized combination: Isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris-A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol 93, 1312–1314 (2025).

    Article  CAS  PubMed  Google Scholar 

  314. Stein Gold, L. et al. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am. J. Clin. Dermatol 23, 93–104 (2022).

    Article  PubMed  Google Scholar 

  315. Aleid, A. et al. Comparative efficacy of clindamycin phosphate with benzoyl peroxide versus clindamycin phosphate with adapalene in acne vulgaris: a systematic review and meta-analysis. Sci. Rep. 15, 20478 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  316. Zeng, Q. et al. Carrier-free cryptotanshinone-peptide conjugates self-assembled nanoparticles: An efficient and low-risk strategy for acne vulgaris. Asian J. Pharm. Sci. 19, 100946 (2024).

    PubMed  PubMed Central  Google Scholar 

  317. Zhang, J. et al. Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up. Dermatol Ther. (Heidelb.) 15, 3285–3300 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  318. Mavranezouli, I. et al. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Br. J. Dermatol 187, 639–649 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  319. Vallerand, I. A. et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br. J. Dermatol 178, 76–85 (2018).

    Article  CAS  PubMed  Google Scholar 

  320. Lai, J. & Barbieri, J. S. Acne Relapse and Isotretinoin Retrial in Patients With Acne. JAMA Dermatol 161, 367–374 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  321. Mahase, E. Isotretinoin: Regulator adds prescribing safeguards after review of side effects. BMJ 383, 2545 (2023).

    Article  PubMed  Google Scholar 

  322. Hill, R. C., Wang, Y., Shaikh, B. & Lipner, S. R. Future research directions regarding safety of spironolactone for dermatologic conditions. J. Am. Acad. Dermatol 91, e173–e174 (2024).

    Article  CAS  PubMed  Google Scholar 

  323. Barros, A. et al. In vivo confocal microscopy provides evidence of corneal nerve damage and basal tear film reduction in patients treated with oral isotretinoin. J. Transl. Med 23, 550 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  324. Del Rosso, J. Q., Rosen, T., Palceski, D. & Rueda, M. J. Patient Awareness of Antimicrobial Resistance and Antibiotic Use in Acne Vulgaris. J. Clin. Aesthet. Dermatol 12, 30–41 (2019).

    PubMed  PubMed Central  Google Scholar 

  325. Santer, M. et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicenter, phase 3, double blind, randomized controlled trial. BMJ 381, e074349 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  326. Garg, V., Choi, J. K., James, W. D. & Barbieri, J. S. Long-term use of spironolactone for acne in women: A case series of 403 patients. J. Am. Acad. Dermatol 84, 1348–1355 (2021).

    Article  CAS  PubMed  Google Scholar 

  327. Hill, R. C., Wang, Y., Shaikh, B. & Lipner, S. R. No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study. J. Am. Acad. Dermatol 90, 1302–1304 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  328. Pyne, S. et al. Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomized controlled trial. BMJ Open 13, e073245 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  329. Thiboutot, D. M. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J. Am. Acad. Dermatol 78, S1–S23.e21 (2018).

    Article  PubMed  Google Scholar 

  330. Bandyopadhyay, D. Topical Antibacterials in Dermatology. Indian J. Dermatol 66, 117–125 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  331. Del Rosso, J. et al. Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol 89, 719–727 (2023).

    Article  PubMed  Google Scholar 

  332. Habeshian, K. A. & Cohen, B. A. Current Issues in the Treatment of Acne Vulgaris. Pediatrics 145, S225–S230 (2020).

    Article  PubMed  Google Scholar 

  333. Palli, M. B., Reyes-Habito, C. M., Lima, X. T. & Kimball, A. B. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3 mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J. Drugs Dermatol. 12, 633–637 (2013).

    CAS  PubMed  Google Scholar 

  334. Melnik, B. C. Olumacostat Glasaretil, a Promising Topical Sebum-Suppressing Agent that Affects All Major Pathogenic Factors of Acne Vulgaris. J. Invest. Dermatol 137, 1405–1408 (2017).

    Article  CAS  PubMed  Google Scholar 

  335. Bissonnette, R., Poulin, Y., Drew, J., Hofland, H. & Tan, J. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. J. Am. Acad. Dermatol 76, 33–39 (2017).

    Article  CAS  PubMed  Google Scholar 

  336. ClinicalTrials.gov. A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris. ClinicalTrials.gov (2021).

  337. Heymann, W. R. Expanding the therapeutic versatility of clacosterone. J. Am. Acad. Dermatol 90, 43–44 (2024).

    Article  CAS  PubMed  Google Scholar 

  338. Hebert, A. et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol 156, 621–630 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  339. Mhatre, M., Sharma, A. & Agrawal, S. Topical tacrolimus for acne-related macular erythema to prevent atrophic scarring. J. Am. Acad. Dermatol 86, e253–e254 (2022).

    Article  CAS  PubMed  Google Scholar 

  340. Veenstra, J., Ozog, D. & Stephens, A. Benzoyl peroxide acne treatment shows no significant association with benzene-related cancers: A multicenter retrospective analysis. J. Am. Acad. Dermatol 92, 1440–1442 (2025).

    Article  CAS  PubMed  Google Scholar 

  341. Sadr, N., Troger, A., Chai, P. R. & Barbieri, J. S. No evidence for an association between benzoyl peroxide use and increased blood benzene levels in the National Health and Nutrition Examination Survey. J. Am. Acad. Dermatol 91, 763–765 (2024).

    Article  CAS  PubMed  Google Scholar 

  342. Neubauer, Z. J. K. & Lipner, S. R. No association between isotretinoin and sexual dysfunction in a large retrospective cohort study of acne patients. J. Am. Acad. Dermatol 93, 802–803 (2025).

    Article  PubMed  Google Scholar 

  343. Heerfordt, I. M., Tulstrup, M. & Horwitz, H. No association between acne treatment with retinoids and suicide attempts in adolescents: A case‒control study. J. Am. Acad. Dermatol 92, 583–585 (2025).

    Article  CAS  PubMed  Google Scholar 

  344. Ugonabo, N. et al. Psychiatric disorders and suicidal behavior in patients with acne prescribed oral antibiotics versus isotretinoin: Analysis of a large commercial insurance claims database. J. Am. Acad. Dermatol 85, 878–884 (2021).

    Article  CAS  PubMed  Google Scholar 

  345. Biesman, B. S. et al. Treatment of Atrophic Facial Acne Scars With Microneedling Followed by Polymethylmethacrylate-Collagen Gel Dermal Filler. Dermatol Surg. 45, 1570–1579 (2019).

    Article  CAS  PubMed  Google Scholar 

  346. Zhao, T. et al. Comparison of the Effects of Adipose Extracellular Matrix/Stromal Vascular Fraction Gel Injection and CO(2) Fractional Laser on Atrophic Acne Scar in Asians Through a 24-Week Prospective, Randomized, Split-Face Study. J. Cosmet. Dermatol 24, e70131 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  347. Alexiades, M., Kothare, A., Goldberg, D. & Dover, J. S. Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types. J. Am. Acad. Dermatol 89, 703–710 (2023).

    Article  CAS  PubMed  Google Scholar 

  348. Ishii, L., Deoghare, S. & Boen, M. Light and laser-based therapy in treatment of acne vulgaris: A clinical review. J. Am. Acad. Dermatol 93, 1058–1064 (2025).

    Article  CAS  PubMed  Google Scholar 

  349. Goldberg, D. et al. Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study. J. Am. Acad. Dermatol. 94, 517–524 (2026).

  350. Pavlackova, J. et al. The Effect of Cosmetic Treatment and Gel Laser Therapy on the Improvement of Comedogenic Skin Type. Gels 9, 370 (2023).

  351. Tang, X., Li, C., Ge, S., Chen, Z. & Lu, L. Efficacy of photodynamic therapy for the treatment of inflammatory acne vulgaris: A systematic review and meta-analysis. J. Cosmet. Dermatol 19, 10–21 (2020).

    Article  PubMed  Google Scholar 

  352. Anderer, S. At-Home LED Devices May Show Promise for Acne Treatment. JAMA 333, 1478 (2025).

    PubMed  Google Scholar 

  353. Zhang, L. et al. Modified red light 5-aminolevulinic acid photodynamic therapy versus low-dose isotretinoin therapy for moderate to severe acne vulgaris: A prospective, randomized, multicenter study. J. Am. Acad. Dermatol 89, 1141–1148 (2023).

    Article  CAS  PubMed  Google Scholar 

  354. Zhang, Y. et al. Modified 5-aminolevulinic acid photodynamic therapy to reduce pain in the treatment of moderate to severe acne vulgaris: A prospective, randomized, split-face study. J. Am. Acad. Dermatol 84, 218–220 (2021).

    Article  CAS  PubMed  Google Scholar 

  355. Rossi, F. et al. Photobiomodulation of Human Fibroblasts and Keratinocytes with Blue Light: Implications in Wound Healing. Biomedicines 9, 41 (2021).

  356. Wu, Y., Deng, Y. & Huang, P. Application of red light therapy for moderate-to-severe acne vulgaris: A systematic review and meta-analysis. J. Cosmet. Dermatol 20, 3498–3508 (2021).

    Article  PubMed  Google Scholar 

  357. Baroni, A. & Verolino, P. Plasma Radiofrequency Ablation for Scar Treatment. J. Clin. Med. 11, 140 (2021).

  358. Chutoprapat, R. et al. Development of solid lipid microparticles (SLMs) containing asiatic acid for topical treatment of acne: Characterization, stability, in vitro and in vivo anti-acne assessment. Int J. Pharm. 654, 123980 (2024).

    Article  CAS  PubMed  Google Scholar 

  359. An, M. K., Hong, E. H., Suh, S. B., Park, E. J. & Kim, K. H. Combination Therapy of Microneedle Fractional Radiofrequency and Topical Poly-Lactic Acid for Acne Scars: A Randomized Controlled Split-Face Study. Dermatol Surg. 46, 796–802 (2020).

    Article  CAS  PubMed  Google Scholar 

  360. Ali, B., ElMahdy, N. & Elfar, N. N. Microneedling (Dermapen) and Jessner’s solution peeling in treatment of atrophic acne scars: a comparative randomized clinical study. J. Cosmet. Laser Ther. 21, 357–363 (2019).

    Article  PubMed  Google Scholar 

  361. Eichenfield, L. F. et al. DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol 89, 945–951 (2023).

    Article  CAS  PubMed  Google Scholar 

  362. Yang, B. et al. Solution blow spun bilayer chitosan/polylactic acid nanofibrous patch with antibacterial and anti-inflammatory properties for accelerating acne healing. Carbohydr. Polym. 326, 121618 (2024).

    Article  CAS  PubMed  Google Scholar 

  363. Xiang, Y. et al. Ultrasound-triggered interfacial engineering-based microneedle for bacterial infection acne treatment. Sci. Adv. 9, eadf0854 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  364. Park, J., Kim, J., Fakhraei Lahiji, S. & Kim, Y. H. Dual-Phase Antibacterial and Anti-inflammatory Self-Locking Microarray Patches for the Effective Treatment of Acne Vulgaris. ACS Appl. Mater. Interfaces 17, 45438–45447 (2025).

    Article  CAS  PubMed  Google Scholar 

  365. Wang, Q. et al. Dissolving Hyaluronic Acid-Based Microneedles to Transdermally Deliver Eugenol Combined with Photothermal Therapy for Acne Vulgaris Treatment. ACS Appl. Mater. Interfaces 16, 21595–21609 (2024).

    Article  CAS  PubMed  Google Scholar 

  366. Maisel, A. et al. Self-reported Patient Motivations for Seeking Cosmetic Procedures. JAMA Dermatol. 154, 1167–1174 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  367. Bilal, H. et al. Stabilization of Acne Vulgaris-Associated Microbial Dysbiosis with 2% Supramolecular Salicylic Acid. Pharmaceuticals (Basel) 16, 87 (2023).

  368. Shao, X. et al. Effect of 30% Supramolecular Salicylic Acid Peel on Skin Microbiota and Inflammation in Patients with Moderate-to-Severe Acne Vulgaris. Dermatol Ther. (Heidelb.) 13, 155–168 (2023).

    Article  PubMed  Google Scholar 

  369. Yuan, M. et al. Comprehensive analysis of salicylic acid-derivatized alginate: Synthesis, characterization, and anti-acne potential. Carbohydr. Polym. 364, 123776 (2025).

    Article  CAS  PubMed  Google Scholar 

  370. Alvarez, G. V. et al. Skincare ingredients recommended by cosmetic dermatologists: A Delphi consensus study. J. Am. Acad. Dermatol 93, 1509–1525 (2025).

    Article  PubMed  Google Scholar 

  371. Cooper, A. J. & Harris, V. R. Modern management of acne. Med J. Aust. 206, 41–45 (2017).

    Article  PubMed  Google Scholar 

  372. Barbieri, J. S., Spaccarelli, N., Margolis, D. J. & James, W. D. Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J. Am. Acad. Dermatol 80, 538–549 (2019).

    Article  PubMed  Google Scholar 

  373. Zhang, F. et al. ZnO colludes with C. acnes in healing delay and Scar hyperplasia by barrier destruction. J. Nanobiotechnology 23, 404 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  374. Chovatiya, R. Acne Treatment. JAMA 326, 2087 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  375. Jennings, T. et al. Acne scarring-pathophysiology, diagnosis, prevention and education: Part I. J. Am. Acad. Dermatol 90, 1123–1134 (2024).

    Article  PubMed  Google Scholar 

  376. Delanghe, L. et al. The role of lactobacilli in inhibiting skin pathogens. Biochem Soc. Trans. 49, 617–627 (2021).

    Article  CAS  PubMed  Google Scholar 

  377. De Lucas, R. et al. New clinical approach in facial mild-moderate acne: Restabilization of skin microbiota balance with a topical biotechnological phytocomplex. J. Cosmet. Dermatol 23, 3616–3627 (2024).

    Article  PubMed  Google Scholar 

  378. Fusco, A. et al. Regulatory Ability of Lactiplantibacillus plantarum on Human Skin Health by Counteracting In Vitro Malassezia furfur Effects. J. Fungi (Basel) 9, 1153 (2023).

  379. Lebeer, S. et al. Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli. Cell Rep. Med 3, 100521 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  380. Lopes, E. G. et al. Topical application of probiotics in skin: adhesion, antimicrobial and antibiofilm in vitro assays. J. Appl. Microbiol 122, 450–461 (2017).

    Article  CAS  PubMed  Google Scholar 

  381. Wang, S. et al. Respiration electron of pathogenic bacteria activated ZnO@Viologen-COF heterojunction to boost piezo-phototronic effect for microbiota regulation. Sci. Bull (Beijing) 70, 3600–3613 (2025).

  382. Gu, X. et al. Zinc-Enriched Bifidobacterium longum subsp. longum CCFM1195 Alleviates Cutibacterium acnes-Induced Skin Lesions in Mice by Mitigating Inflammatory Responses and Oxidative Stress. Nutrients 17, 1803 (2025).

  383. Wu, Y., Wang, X., Wu, W. & Yang, J. Mendelian randomization analysis reveals an independent causal relationship between four gut microbes and acne vulgaris. Front Microbiol 15, 1326339 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  384. Deng, Y. et al. Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls. Acta Derm. Venereol. 98, 783–790 (2018).

    Article  CAS  PubMed  Google Scholar 

  385. Yan, H. M. et al. Gut microbiota alterations in moderate to severe acne vulgaris patients. J. Dermatol 45, 1166–1171 (2018).

    Article  CAS  PubMed  Google Scholar 

  386. Huang, Y. et al. Gender-Specific Differences in Gut Microbiota Composition Associated with Microbial Metabolites for Patients with Acne Vulgaris. Ann. Dermatol 33, 531–540 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  387. Huang, Y. et al. The adjuvant treatment role of omega-3 fatty acids by regulating gut microbiota positively in the acne vulgaris. J. Dermatol. Treat. 35, 2299107 (2024).

    Article  Google Scholar 

  388. Huang, Y. et al. Lactobacillus rhamnosus ameliorates acne vulgaris in SD rats via changes in gut microbiota and associated tryptophan metabolism. Front Immunol. 14, 1293048 (2023).

    Article  CAS  PubMed  Google Scholar 

  389. Xu, Y. N. et al. Unveiling acne microbiome signatures: the role of the microbiome and the impact of a facewash formula containing plant-derived monoterpenes. Br. J. Dermatol 193, ii15–ii23 (2025).

    Article  CAS  PubMed  Google Scholar 

  390. Mias, C. et al. Change in Cutibacterium acnes phylotype abundance and improvement of clinical parameters using a new dermocosmetic product containing Myrtus communis and Celastrol enriched plant cell culture extracts in patients with acne vulgaris. J. Eur. Acad. Dermatol Venereol. 37, 20–25 (2023).

    Article  CAS  PubMed  Google Scholar 

  391. Mias, C. et al. Myrtus communis and Celastrol enriched plant cell culture extracts control together the pivotal role of Cutibacterium acnes and inflammatory pathways in acne. J. Eur. Acad. Dermatol Venereol. 37, 12–19 (2023).

    Article  CAS  PubMed  Google Scholar 

  392. Carballido, F. et al. A dermocosmetic product containing the sap of oat plantlets and Garcinia mangostana extract improves the clinical signs of acne. J. Eur. Acad. Dermatol Venereol. 38, 12–20 (2024).

    Article  PubMed  Google Scholar 

  393. Chen, Q. et al. Insights into microbial dysbiosis and Cutibacterium acnes CAMP factor interactions in acne vulgaris. Microb. Genom 11, 001449 (2025).

  394. Naseeb, J. et al. Network pharmacology-guided probiotic metabolite therapy for acne vulgaris to target Cutibacterium acnes CAMP factors through Pediococcus acidilactici BCBH1 fatty acids. Allergol. Immunopathol. (Madr.) 53, 126–140 (2025).

    Article  PubMed  Google Scholar 

  395. Lheure, C. et al. TLR-2 Recognizes Propionibacterium acnes CAMP Factor 1 from Highly Inflammatory Strains. PLoS One 11, e0167237 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  396. Plackett, B. Acne vaccines could offer robust defense. Nature 644, S22 (2025).

    Article  CAS  PubMed  Google Scholar 

  397. Administration, C. N. M. P. WSK-V108E. (Center for Drug Evaluation (CDE), National Medical Products Administration, 2025).

  398. Immorna. Immorna therapeutic mRNA vaccine for acne, JCXH-401, receives FDA approval for clinical trials in the United States. (2025).

  399. Sandoval, A. G. W., Vaughn, L. T., Huang, J. T. & Barbieri, J. S. Role of Tumor Necrosis Factor-alpha Inhibitors in the Treatment and Occurrence of Acne: A Systematic Review. JAMA Dermatol 159, 504–509 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  400. Nasseh, J. et al. Efficacy of tumor necrosis factor-alpha inhibitors in the treatment of isotretinoin-induced acne fulminans. J. Eur. Acad. Dermatol Venereol. 38, e96–e98 (2024).

    Article  CAS  PubMed  Google Scholar 

  401. Pinto Salgueiro, G., Yilmaz, O., Nogueira, M. & Torres, T. Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa. BioDrugs 39, 53–74 (2025).

    Article  PubMed  Google Scholar 

  402. Nikolakis, G. et al. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Res 10, 381 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  403. Fournier, J. F. et al. Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne. J. Med Chem. 61, 4030–4051 (2018).

    Article  CAS  PubMed  Google Scholar 

  404. Devakrishnan, P., Nasir, N. M., Hasan, H., Tejo, B. A. & Baharuddin, F. F. Synthesis, in vitro and in silico evaluation of halogenated xanthone and benzophenone derivatives as antibacterial agents against acne-causing bacteria. Bioorg. Chem. 164, 108906 (2025).

    Article  CAS  PubMed  Google Scholar 

  405. Abd-Allah, H., Ragaie, M. H. & Elmowafy, E. Unraveling the pharmaceutical and clinical relevance of the influence of syringic acid loaded linoleic acid transferosomes on acne. Int J. Pharm. 639, 122940 (2023).

    Article  CAS  PubMed  Google Scholar 

  406. Ain, N. U. et al. Fabrication of mesoporous silica nanoparticles for releasable delivery of licorice polysaccharide at the acne site in topical application. Carbohydr. Polym. 339, 122250 (2024).

    Article  CAS  PubMed  Google Scholar 

  407. Kola-Mustapha, A. T., Raji, M. A., Zarroug, S. H. O. & Ambrose, G. O. Gentamicin and Citronella-Derived Compounds as Dual Modulators of Inflammation-Associated Targets in Acne Vulgaris. Int. J. Mol. Sci. 26, 10628 (2025).

  408. Luczak, J. W. et al. The Next Generation of Skin Care: Transforming Retinoid Therapeutics. Cells 14, 1650 (2025).

  409. Domaszewska-Szostek, A., Krzyzanowska, M., Polak, A. & Puzianowska-Kuznicka, M. Effectiveness of Extracellular Vesicle Application in Skin Aging Treatment and Regeneration: Do We Have Enough Evidence from Clinical Trials? Int. J. Mol. Sci. 26, 2354 (2025).

  410. Majewska, L., Kondraciuk, A., Dorosz, K. & Budzynska, A. Application of Standardized Rosa damascena Stem Cell-Derived Exosomes in Dermatological Wound Healing and Scar Management: A Retrospective Case-Series Study with Long-Term Outcome Assessment. in Pharmaceutics, 17, 910 (2025).

  411. Gong, G., Yun, M., Kwon, O. & Kim, B. Therapeutic and Pharmaceutical Potential of Scutellaria baicalensis-Derived Exosomes for Oily Skin Disorders. Antioxidants (Basel) 14, 364 (2025).

  412. Rau, C. S., Kuo, P. J. & Hsieh, C. H. Adipose-derived stem cell exosomes: multifaceted therapeutic applications in regenerative medicine. Int J. Surg. 111, 7099–7113 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  413. Ma, Z., Kochergin, N., Olisova, O. & Snarskaya, E. Topical antimicrobial peptides in combined treatment of acne patients. J. Cosmet. Dermatol 21, 1533–1538 (2022).

    Article  PubMed  Google Scholar 

  414. Li, M. et al. Trp-containing Peptides with Therapeutic Potential for Cutibacterium acnes Infection. Probiotics Antimicrob. Proteins 18, 4169-4184 (2025).

  415. Liao, M. et al. Combination of a pH-responsive peptide amphiphile and a conventional antibiotic in treating gram-negative bacteria. J. Colloid Interface Sci. 659, 397–412 (2024).

    Article  CAS  PubMed  Google Scholar 

  416. Han, R., Blencke, H. M., Cheng, H. & Li, C. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris. Peptides 99, 36–43 (2018).

    Article  CAS  PubMed  Google Scholar 

  417. Wu, Y., Zhang, G. & Zhou, M. Inhibitory and anti-inflammatory effects of two antimicrobial peptides moronecidin and temporin-1Dra against Propionibacterium acnes in vitro and in vivo. J. Pept. Sci. 26, e3255 (2020).

    Article  CAS  PubMed  Google Scholar 

  418. Center for Drug Evaluation (CDE), N.M.P.A.N. PD-DP-008. (Center for Drug Evaluation, National Medical Products Administration, 2024).

  419. Rihova, M. et al. Centrifugally spun and ZnO-infiltrated PVA fibers with antibacterial activity for treatment of Acne vulgaris. J. Control Release 383, 113777 (2025).

    Article  CAS  PubMed  Google Scholar 

  420. Zhao, T. et al. Dendrimer-conjugated isotretinoin for controlled transdermal drug delivery. J. Nanobiotechnol. 21, 285 (2023).

    Article  CAS  Google Scholar 

  421. Jiang, C. et al. Chitosan membrane tailored for topical acne treatment by incorporating Pickering encapsulated tea tree oil based on organosilane-modified palygorskite. Int J. Biol. Macromol. 321, 146317 (2025).

    Article  CAS  PubMed  Google Scholar 

  422. Folle, C. et al. Hydrogel of Thyme-Oil-PLGA Nanoparticles Designed for Skin Inflammation Treatment. Gels 10, 149 (2024).

  423. Li, X. et al. vB_CacS-HV1 as a Novel Pahexavirus Bacteriophage with Lytic and Anti-Biofilm Potential against Cutibacterium acnes. Microorganisms 12, 1566 (2024).

  424. Liu, Y. et al. Application of bacteriophage phiPaP11-13 attenuates rat Cutibacterium acnes infection lesions by promoting keratinocytes apoptosis by inhibiting PI3K/Akt pathway. Microbiol Spectr. 12, e0283823 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  425. Rimon, A. et al. Topical phage therapy in a mouse model of Cutibacterium acnes-induced acne-like lesions. Nat. Commun. 14, 1005 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  426. Lee, J. H., Hasnain, M. A., Park, J. H., Choi, W. & Moon, G. S. Comparative antibacterial activity of N-terminal and C-terminal domains of a recombinant endolysin against Cutibacterium acnes. Appl Environ. Microbiol 91, e0116825 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  427. Ghumra, W. et al. MicroRNAs as biomarkers of atrophic scarring in acne: a cross-sectional analysis of 41 patients. Clin. Exp. Dermatol 46, 1495–1503 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Figdraw.com is thanked for creating images. This study was supported by the National Key R&D Program of China for Innovative Drug Development (Grant No. 2025ZD1804204), the Natural Science Foundation of Sichuan Province (Grant No. 2025ZNSFSC0663), and the National Natural Science Foundation of China (General Program, Grant No. 82371852).

Author information

Author notes

  1. These authors contributed equally: Ya Li, Guolin Li, Lian Wang

Authors and Affiliations

  1. Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

    Ya Li, Guolin Li & Jiong Li

  2. Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China

    Lian Wang, Dan Du, Jiaqi Li, Deyu Song, Tong Li & Xian Jiang

  3. Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    Ping Feng

  4. Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

    Xian Jiang

Authors

  1. Ya Li
  2. Guolin Li
  3. Lian Wang
  4. Dan Du
  5. Jiaqi Li
  6. Deyu Song
  7. Tong Li
  8. Ping Feng
  9. Xian Jiang
  10. Jiong Li

Contributions

Ya Li, Jiong Li and Xian Jiang participated in the conception and design of this review; Ya Li, Guolin Li and Lian Wang wrote the manuscript and generated the manuscript’s figures; Dan Du, Jiaqi Li, Deyu Song, Tong Li, and Ping Feng contributed to critical revision of the manuscript, literature analysis, improvement of the treatment and pathogenesis sections, and coordination of the revised manuscript; and Xian Jiang supervised this work. All the authors have read, reviewed, and approved the article.

Corresponding authors

Correspondence to Ping Feng, Xian Jiang or Jiong Li.

Ethics declarations

Competing interests

This work was supported by WestVac Biopharma Co. Ltd. Jiong Li is working at WestVac Biopharma Co. Ltd. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Li, G., Wang, L. et al. Acne: epidemiology, risk factors, pathogenesis, management and cutting-edge research. Sig Transduct Target Ther 11, 446 (2026). https://doi.org/10.1038/s41392-026-02964-2

Download citation

  • Received: 27 December 2025

  • Revised: 06 July 2026

  • Accepted: 16 July 2026

  • Published: 13 October 2026

  • Version of record: 13 October 2026

  • DOI: https://doi.org/10.1038/s41392-026-02964-2

来源:Nature 健康护理主题 · nature.com